[go: up one dir, main page]

US20040192702A1 - Heteroaryl alkyl piperazine derivatives - Google Patents

Heteroaryl alkyl piperazine derivatives Download PDF

Info

Publication number
US20040192702A1
US20040192702A1 US10/813,743 US81374304A US2004192702A1 US 20040192702 A1 US20040192702 A1 US 20040192702A1 US 81374304 A US81374304 A US 81374304A US 2004192702 A1 US2004192702 A1 US 2004192702A1
Authority
US
United States
Prior art keywords
compound
acetamide
yloxy
hydroxy
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/813,743
Inventor
Jeff Zablocki
Prabha Ibrahim
Kevin Shenk
Elfatih Elzein
Venkata Palle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/813,743 priority Critical patent/US20040192702A1/en
Publication of US20040192702A1 publication Critical patent/US20040192702A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Definitions

  • the present invention is concerned with piperazine derivatives, therapeutic dosage forms including one or more of the derivatives, and methods for treating diseases in mammals, and in particular, in a human in a therapy selected from the group including diabetes, protecting skeletal muscles against damage resulting from diabetes, trauma, protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
  • a therapy selected from the group including diabetes, protecting skeletal muscles against damage resulting from diabetes, trauma, protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise
  • U.S. Pat. No. 4,567,264 discloses a class of substituted piperazine compounds that includes a compound known as ranolazine, ( ⁇ )-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]-1-piperazineacetamide, and its pharmaceutically acceptable salts, and their use in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise-induced angina, and myocardial infarction.
  • ranolazine a compound known as ranolazine
  • ( ⁇ )-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]-1-piperazineacetamide and its pharmaceutically acceptable salts, and their use in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise-induced angina, and myocardial infarction.
  • U.S. Pat. No. 5,506,229 which is incorporated herein by reference, discloses the use of ranolazine and its pharmaceutically acceptable salts and esters for the treatment of tissues experiencing a physical or chemical insult, including cardioplegia, hypoxic or reperfusion injury to cardiac or skeletal muscle or brain tissue, and for use in transplants.
  • ranolazine is particularly useful for treating arrhythmias, variant and exercise-induced angina, and myocardial infarction by partially inhibiting cardiac fatty acid oxidation.
  • Conventional oral and parenteral ranolazine formulations are disclosed, including controlled release formulations.
  • Example 7D of U.S. Pat. No. 5,506,229 describes a controlled release formulation in capsule form comprising microspheres of ranolazine and microcrystalline cellulose coated with release controlling polymers.
  • ranolazine is a very useful cardiac therapeutic agent
  • Several of such compounds are disclosed in U.S. patent application Ser. No. 09/694,155, filed Oct. 23, 2001.
  • We have now discovered other compounds that are useful as partial inhibitors of oxidation including specific enantiomers and diastereoisomers, and also that such compounds are useful in the treatment of other disease states, including diabetes and atrial and ventricular arrhythmia.
  • This invention includes novel heteroaryl alkyl piperazine derivatives that are partial fatty acid oxidation inhibitors with good therapeutic half-lives.
  • This invention also includes novel substituted piperazine compounds that can be administered to a mammal to protect skeletal muscles against damage resulting from trauma, to protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
  • novel substituted piperazine compounds that can be administered to a mammal to protect skeletal muscles against damage resulting from trauma, to protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
  • This invention includes a class of substituted piperazine compounds having the formula:
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , and SO 2 R 22
  • R 6 , R 7 and R 8 each independently selected from the group consisting of hydrogen and C 1-3 alkyl;
  • R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of hydrogen, CO 2 R 20 , CON(R 20 ) 2 , C 1-4 alkyl, and aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF 3 , CN, OR 20 , —N(R 20 ) 2 , —CO 2 R 20 , —CON(R 20 ) 2 and aryl, wherein R 9 and R 10 may together form a carbonyl, or R 11 and R 12 may together form a carbonyl, or R 13 and R 14 may together form a carbonyl, or R 15 and R 16 may together form a carbonyl or R 11 and R 13 or R 9 and R 15 or R 9 and R 11 may join together to form a ring including from 1 to 3 carbon
  • R 17 is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , and SO 2 R
  • R 20 is selected from the group consisting of H, C 1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono- or dialkylamino, alkyl, CN, —O—C 1-6 alkyl, and CF 3 ; and
  • R 22 is selected from the group consisting of C 1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O—C 1-6 alkyl, CF 3 , and heteroaryl.
  • Preferred compounds include:
  • this invention is a method for using one or more compounds of the invention to a mammal to treat a disease selected from the group consisting of diabetes, protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle, systemic diseases such as intermittent claudication, shock conditions, preserving donor tissue and organs used in transplants, and cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
  • a disease selected from the group consisting of diabetes, protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle, systemic diseases such as intermittent claudication, shock conditions, preserving donor tissue and organs used in transplants, and cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , and SO 2 R 22
  • R 6 , R 7 and R 8 each independently selected from the group consisting of hydrogen and C 1-3 alkyl;
  • R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are each independently selected from the group consisting of hydrogen, CO 2 R 20 , CON(R 20 ) 2 , C 1-4 alkyl, and aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF 3 , CN, OR 20 , N(R 20 ) 2 , —CO 2 R 20 , —CON(R 20 ) 2 and aryl, wherein R 9 and R 10 may together form a carbonyl, or R 11 and R 12 may together form a carbonyl, or R 13 and R 14 may together form a carbonyl, or R 15 and R 16 may together form a carbonyl or R 11 and R 13 or R 9 and R 15 or R 9 and R 11 may join together to form a ring including from 1 to 3 carbon atoms
  • R 17 is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 SO 2 R 22 , C 1-15 alkyl, C 2-15 alkenyl, C 2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , and SO 2 R
  • R 20 is selected from the group consisting of H, C 1-15 alkyl, aryl, and heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono and dialkylamino, alkyl, CN, —O—C 1-6 alkyl, and CF 3 ; and
  • R 22 is selected from the group consisting of C 1-15 alkyl, aryl, and heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, —O—C 1-6 alkyl, CF 3 , and heteroaryl.
  • Halo or “Halogen”—alone or in combination means all halogens, that is, chloro (Cl), fluoro (F), bromo (Br), iodo (I).
  • Haldroxyl refers to the group —OH.
  • Thiol or “mercapto” refers to the group —SH.
  • Alkyl alone or in combination means an alkane-derived radical containing from 1 to 20, preferably 1 to 15, carbon atoms (unless specifically defined). It is a straight chain alkyl, branched alkyl or cycloalkyl. Preferably, straight or branched alkyl groups containing from 1-15, more preferably 1 to 8, even more preferably 1-6, yet more preferably 1-4 and most preferably 1-2, carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl and the like.
  • the term “lower alkyl” is used herein to describe the straight chain alkyl groups described immediately above.
  • cycloalkyl groups are monocyclic, bicyclic or tricyclic ring systems of 3-8, more preferably 3-6, ring members per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like.
  • Alkyl also includes a straight chain or branched alkyl group that contains or is interrupted by a cycloalkyl portion. The straight chain or branched alkyl group is attached at any available point to produce a stable compound. Examples of this include, but are not limited to, 4-(isopropyl)-cyclohexylethyl or 2-methyl-cyclopropylpentyl.
  • a substituted alkyl is a straight chain alkyl, branched alkyl, or cycloalkyl group defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbon
  • Alkenyl alone or in combination means a straight, branched, or cyclic hydrocarbon containing 2-20, preferably 2-17, more preferably 2-10, even more preferably 2-8, most preferably 2 to 4 carbon atoms with at least one, preferably 1-3, more preferably 1-2, and most preferably one, carbon to carbon double bond.
  • a cycloalkyl group conjugation of more than one carbon to carbon double bond is not such as to confer aromaticity to the ring.
  • Carbon to carbon double bonds may be either contained within a cycloalkyl portion, with the exception of cyclopropyl, or within a straight chain or branched portion.
  • alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, cyclohexenyl, cyclohexenylalkyl and the like.
  • a substituted alkenyl is the straight chain alkenyl, branched alkenyl or cycloalkenyl group defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, amino sulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups
  • Alkynyl alone or in combination means a straight or branched hydrocarbon containing 2-20, preferably 2-17, more preferably 2-10, even more preferably 2-8, most preferably 2-4, carbon atoms containing at least one, preferably one, carbon to carbon triple bond.
  • alkynyl groups include ethynyl, propynyl, butynyl and the like.
  • a substituted alkynyl refers to the straight chain alkynyl or branched alkynyl defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonyla
  • Alkyl alkenyl refers to a group —R—CR′ ⁇ CR′′′R′′′′, where R is lower alkyl, or substituted lower alkyl, R′, R′′′, R′′′′ may independently be hydrogen, halogen, lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined below.
  • Alkyl alkynyl refers to a groups —RC ⁇ OCR′ where R is lower alkyl or substituted lower alkyl, R′ is hydrogen, lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined below.
  • Alkoxy denotes the group —OR, where R is lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroalkyl, heteroarylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, or substituted cycloheteroalkyl as defined.
  • Acyl denotes groups —C(O)R, where R is hydrogen, lower alkyl substituted lower alkyl, aryl, substituted aryl and the like as defined herein.
  • Aryloxy denotes groups —OAr, where Ar is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl group as defined herein.
  • Amino denotes the group NRR′, where R and R′ may independently by hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined herein or acyl.
  • “Amido” denotes the group —C(O)NRR′, where R and R′ may independently by hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, substituted hetaryl as defined herein.
  • Carboxyl denotes the group —C(O)OR, where R is hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, and substituted hetaryl as defined herein.
  • Aryl alone or in combination means phenyl or naphthyl optionally carbocyclic fused with a cycloalkyl of preferably 5-7, more preferably 5-6, ring members and/or optionally substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfon
  • Substituted aryl refers to aryl optionally substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • functional groups e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Heterocycle refers to a saturated, unsaturated, or aromatic carbocyclic group having a single ring (e.g., morpholino, pyridyl or turyl) or multiple condensed rings (e.g., naphthpyridyl, quinoxalyl, quinolinyl, indolizinyl or benzo[b]thienyl) and having at least one hetero atom, such as N, O or S, within the ring, which can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • a single ring e.g., morpholino, pyri
  • Heteroaryl alone or in combination means a monocyclic aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing one or more, preferably 1-4, more preferably 1-3, even more preferably 1-2, heteroatoms independently selected from the group O, S, and N, and optionally substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroary
  • Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen.
  • a carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable aromatic ring is retained.
  • heteroaryl groups are pyridinyl, pyridazinyl, pyrazinyl, quinazolinyl, purinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazinyl, furanyl, benzofuryl, indolyl, benzothiazolyl, benzoxazolyl, and the like.
  • a substituted heteroaryl contains a substituent attached at an available carbon or nitrogen to produce a stable compound.
  • Heterocyclyl alone or in combination means a non-aromatic cycloalkyl group having from 5 to 10 atoms in which from 1 to 3 carbon atoms in the ring are replaced by heteroatoms of O, S or N, and are optionally benzo fused or fused heteroaryl of 5-6 ring members and/or are optionally substituted as in the case of cycloalkyl.
  • Heterocycyl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. The point of attachment is at a carbon or nitrogen atom.
  • heterocyclyl groups are tetrahydrofuranyl, dihydropyridinyl, piperidinyl, pyrrolidinyl, piperazinyl, dihydrobenzoflryl, dihydroindolyl, and the like.
  • a substituted hetercyclyl contains a substituent nitrogen attached at an available carbon or nitrogen to produce a stable compound.
  • Substituted heteroaryl refers to a heterocycle optionally mono or poly substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • functional groups e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Aryl group refers to the group —R—Ar where Ar is an aryl group and R is lower alkyl or substituted lower alkyl group.
  • Aryl groups can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Heteroalkyl refers to the group —R-Het where Het is a heterocycle group and R is a lower alkyl group. Heteroalkyl groups can optionally be unsubstituted or substituted with e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Heteroarylalkyl refers to the group -R-HetAr where HetAr is an heteroaryl group and R lower alkyl or substituted lower alkyl.
  • Heteroarylalkyl groups can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Cycloalkyl refers to a divalent cyclic or polycyclic alkyl group containing 3 to 15 carbon atoms.
  • Substituted cycloalkyl refers to a cycloalkyl group comprising one or more substituents with, e.g., halogen, lower alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Cycloheteroalkyl refers to a cycloalkyl group wherein one or more of the ring carbon atoms is replaced with a heteroatom (e.g., N, O, S or P).
  • Substituted cycloheteroalkyl refers to a cycloheteroalkyl group as herein defined which contains one or more substituents, such as halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • substituents such as halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Alkyl cycloalkyl denotes the group —R-cycloalkyl where cycloalkyl is a cycloalkyl group and R is a lower alkyl or substituted lower alkyl.
  • Cycloalkyl groups can optionally be unsubstituted or substituted with e.g. halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • Alkyl cycloheteroalkyl denotes the group —R-cycloheteroalkyl where R is a lower alkyl or substituted lower alkyl.
  • Cycloheteroalkyl groups can optionally be unsubstituted or substituted with e.g. halogen, lower alkyl, lower alkoxy, alkylthio, amino, amido, carboxyl, acetylene, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.
  • “Optional” and “optionally” mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
  • “optional pharmaceutical excipients” indicates that a formulation so described may or may not include pharmaceutical excipients other than those specifically stated to be present, and that the formulation so described includes instances in which the optional excipients are present and instances in which they are not.
  • Treating” and “treatment” refer to any treatment of a disease in a mammal, particularly a human, and include:
  • All of the aforementioned embodiments include the pharmaceutically acceptable acid addition salts thereof, particularly the mono- and dihydrochlorides, and mixtures thereof.
  • a general synthesis of the compounds of this invention is outlined in Scheme 1.
  • Compound IV can be prepared by N-acylation of substituted aniline II with 2-substituted chloroacetylchloride III.
  • Compound II is available commercially or readily prepared through reduction of the corresponding nitrobenzene derivative (acid/SnCl 2 or catalytic hydrogenation, see Advanced Organic Chemistry, Ed. J. March, (1992) A. Wiley-Interscience).
  • Some examples of commercially available substituted anilines corresponding to general structure II include 2,6-dimethylaniline, 2,3-dimethylaniline, 2-methylaniline, 4-methylaniline, 4-methylaniline, 2,4-dichloroaniline, 3,4-dichloroaniline, 2,5-dichloroaniline, 2,4-dichloroaniline, 2-chloroaniline, 3-chloroaniline, 2,6-difluoroaniline, 2,5-difluoroaniline, 3,4-difluoroaniline, 2-fluoroaniline, 4-fluoroaniline, 3-fluoroaniline, 2-fluoro-6-chloroaniline, 4-fluoro-3-chloroaniline, 4-acetoxyaniline.
  • compound of Formula I is intended to encompass the compounds of the invention as disclosed, and the pharmaceutically acceptable salts, pharmaceutically acceptable esters, prodrugs, hydrates, and polymorphs of such compounds.
  • the compounds of the invention may possess one or more asymmetric centers, and can be produced as a racemic mixture or as individual enantiomers or diastereoisomers.
  • the number of stereoisomers present in any given compound of Formula I depends upon the number of asymmetric centers present (there are 2n stereoisomers possible where n is the number of asymmetric centers).
  • the individual stereoisomers may be obtained by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolution of the compound of Formula I by conventional means.
  • Stepoisomers are isomers that differ only in the way the atoms are arranged in space.
  • Enantiomers are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term “( ⁇ )” is used to designate a racemic mixture where appropriate.
  • “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
  • the absolute stereochemistry is specified according to the Cahn-Ingold-Prelog RS system.
  • the stereochemistry at each chiral carbon may be specified by either R or S.
  • Resolved compounds whose absolute configuration is unknown are designated (+) or ( ⁇ ) depending on the direction (dextro- or laevorotary) which they rotate the plane of polarized light at the wavelength of the sodium D line.
  • Compound VI can be obtained by reacting compound IV with N-protected substituted piperazine V through warming in an appropriate solvent (e.g. DMF, EtOH). Protection of the nitrogen of compound V is only required when it is useful to control the regiochemistry of the addition of Compound V with compound IV. In some cases, compound V can be obtained from commercial resources.
  • an appropriate solvent e.g. DMF, EtOH.
  • Examples of commercially available compounds corresponding to general structure V include 2-methylpiperazine, 2,5-dimethylpiprazine, 2,6-dimethylpiperazine, 2,3,5,6-tetramethylpiperazine, piperazine-2-carboxylic acid, perhydroquinoxaline, 2-aminomethyl-6-methylpiperazine, 2-aminomethylpiperazine, 2-(o-chlorophenyl)piperazine, and 2-(m-chlorophenyl)piperazine.
  • Deprotection of compound VI can be accomplished using the standard conditions (e.g. for Boc group use TFA, for CBZ and benzyl use hydrogenation).
  • Compound Ia or Ic can be prepared by reacting compound VII with epoxide VIII through warming in an appropriate solvent (ethanol, DMF, CHCl 2 , THF) or by stirring at room temperature in the presence of a lanthamide (III) Lewis acid (Chini, M et al., Tetrahedron Lett., 35: 433-36 (1994).
  • Compound IX can be obtained from commercial resources. Examples of commercially available compounds corresponding to structure IX include 2-methyl-5-hydroxybenzothiazole, 2-hydroxybenzothiazole, 8-hydroxyquinolidine, 6-hydroxyquinoline, 4-hydroxyquinoline, 5-hydroxyisoquinoline, 3-hydroxypyridine, 2-quinoxalinol, and 4-(imidazol-1-yl)phenol. In some cases compound VIII can be obtained from commercial sources. Examples of commercially available compounds corresponding to general structure VIII include 4-glycidyloxy-2-indolecarboxamide.
  • Compound IX can in turn be prepared by the deprotection of the corresponding methyl or benzyl ethers (X) using Lewis acids as shown in Scheme 3 (BBr 3 , BF 3 , etc.—see Advanced Organic Chemistry, Ed. J. March (1992) A. Wiley Intersciences, p 434).
  • Benzyl ethers can also be deprotected by refluxing with palladium hydroxide in ethanol/cyclohexene (see Catalytic hydrogenation over platinum metals, P. N. Rylander, Academic Press, New York, N.Y., (1976) p 464).
  • Commercially available methyl ethers include 6-methoxy-2-methyl-benzothiazole.
  • Compound IX can also be prepared by the diazotization of the corresponding amino compounds (XI) as shown in Scheme 4 (Boggust, W. A and Cocker, W. J. Chem. Soc. 1949, 355).
  • Commercially available amines include 6-amino-benzothiazole.
  • the 6, 5 fused ring system of compound X can be prepared by the cyclization of commercially available ethers of 2-aminophenols, 2-aminothiophenols, or 2-aminoanilines (XII) with orthoesters (XIII) (Musser, J. H. et al., J. Med. Chem. 1985, 28, 1255-1259) or imidates (XIV) (Gregory, G. I. Et al., J. Chem. Soc. Perkin Trans. 1, 1973, 47-51) as shown in Scheme 5 and 6 respectively.
  • ethers of aminophenols include 4-methoxy-2-aminophenol
  • orthoesters include trimethyl orthoformate and trimethyl orthoacetate
  • imidates include ethyl acetimidate hydrochloride, and ethyl benzimidate hydrochloride.
  • the thiophenol analog of compound XII can be prepared from the commercially available compound XV by reacting with sodium disulfide hydrate followed by reduction using tin and hydrochloric acid ( Dannley, R. L. and Zazaris, D. A; Can. J. Chem. 1965, 43, 2610-2612) as shown in Scheme 7.
  • Commercially available nitro compounds include 3-nitro-4-chloroanisole.
  • Imidate XIV can be prepared by bubbling HCl gas through an alcoholic solution of the commercially available nitrites XVI as shown in Scheme 8.
  • Commercially available nitrites include, benzonitrile, 4-trifluoromethylbenzonitrile and 3-trifluoromethylbenzonitrile.
  • Sulfur containing 6,5 fused ring system of compound X can also be prepared from the commercially available ethers of anilines XVII (Stevens, M. F. G. et al, J. Med. Chem. 1994, 37, 1689-1695) as shown in Scheme 9.
  • Thioamide XX can be obtained by the reaction of Lawesson's reagent with amide XIX which in turn can be prepared by the reaction of compound XVII with compound XVIII. Cyclization of XX with potassium ferrocyanide under basic conditions can afford compound XXI.
  • Commercially available ethers of anilines include benzyloxyanilines and anisidines.
  • a general synthesis of the compound XXV of this invention is outlined in Scheme 10.
  • Compound XXIV can be prepared by the deprotection of compound XXIII using the standard conditions (e. g. for BOC group use TFA, for CBZ and benzyl use hydrogenation).
  • Compound XXIII in turn can be prepared by the reaction of the commercially available protected monoketopiperazine analog compound XXII with compound IV and sodium hydride in an appropriate solvent (DMF, THF).
  • An example of the commercially available monoketopiperazines include 4-benzyloxycarbonylpiperazine-2-one.
  • Compound XXVII can be prepared by refluxing compound VII with the epoxide XXVI in a suitable solvent (ethanol, THF). Deprotection of compound XXVII can be accomplished by using standard conditions (e. g. for BOC group use TFA; for CBZ use hydrogenation or Pd(OH) 2 ).
  • Compound Ib can be prepared by refluxing compound XXVIII with compound XXIX in a suitable solvent (ethanol, THF).
  • compound XXIX includes 2-chlorobenzothiazole, 2-chlorobenzoxazole, 2-chloropyridine, 2-chloropyrimidine, 2-chloro-4-(trifluoromethyl)pyrimidine, and chloropyrazine.
  • Epoxide XXVI in turn can be prepared as shown in Scheme 12.
  • Commercially available compound XXX can be protected using the standard conditions (for BOC protection use BOC anhydride; for CBZ protection use CBZ-Cl).
  • Compound XXV can be prepared by the reaction of compound XXXI using m-chloroperbenzoic acid in a suitable solvent (e. g. dichloromethane).
  • An example of a commercially available compound XXX includes by is not limited to allylamine.
  • Compound V can be prepared as described in Scheme 13. Alkylation of compound XXXII with alkyl halides using t-BuLi as base can afford compound XXXIII as described by Pohlman et. al. (J. Org. Chem, 1997, 62, 1016-1022). Reduction of XXXIV using diborane can afford the N-benzyl protected version of compound V after N-Boc deprotection with trifluoroacetic acid (TFA) [for the diborane reduction see Jacobson et. al, J. Med. Chem, 1999, 42, 1123-1144].
  • TFA trifluoroacetic acid
  • Compound V can also be prepared through standard coupling (eg. EDC or PyBroP) of D or L amino acids and standard deprotection as outlined in Scheme 14 (Cledera, P. et al. Tetrahedron, 1998 p. 12349-12360; Smith, R. A. et al Bioorg. Med. Chem. Lett. 1998, p. 2369-2374). Reduction of the diketopiperazine XXXVII with diborane can afford the N-benzyl protected version of compound V.
  • Compound V can also be prepared as described in Scheme 15. Bromination of aldehydes XXXVIII followed by the reaction with ethylene diamine can afford the imine XLI. Catalytic hydrogenation of compound XLI can afford compound V (Bogeso, K. P., et al, J. Med. Chem. 1995, 38, p 4380-4392).
  • Commercially available aldehydes include isobutyraldehyde.
  • Compound V also includes the bicyclic homologs of piperazine (1S,4S)-(+)-2,5-diazabicyclo[2.2.1]heptane 83, 3,8-diazabicyclo[3.2.1]octane 84, and 2,5-diazabicyclo[2.2.2]octane 85.
  • the benzoxazole derivative 8 was prepared by the deprotection of compound 13 as shown in Scheme 18.
  • Compound 10 was prepared by condensation of 2-amino-4-methoxyphenol 12.
  • Compound 12 was obtained by the catalytic hydrogenation of the commercially available 4-methoxy-2-nitrophenol 11, and the benzimidate derivative 13 as shown in Scheme 19.
  • Compound 13 was obtained from 3-trifluoromethylbenzonitrile 14 using a Pinner reaction (ethanol/anhydrous HCl).
  • Compound 22 can be prepared by the reduction of compound 21 with tin and hydrochloric acid as shown in Scheme 23.
  • Compound 21 was synthesized by reacting compound 20 with sodium disulfide hydrate.
  • Compound 26 was prepared by the reaction of compound 25 with Lawesson's reagent as shown in Scheme 24.
  • Compound 25 was prepared by the reaction of the aniline 23 with benzoyl chloride 24. Cyclization of the thioamide 26 with potassium ferrocyanide in aqueous sodium hydroxide gave a mixture of compounds 27 and 28. Compounds 27 and 28 were separated by column chromatography.
  • Epoxide 35 was synthesized as described in Scheme 28. Allylamine 40 was reacted with benzyl chloroformate in dichloromethane to afford compound 42. Reaction of m-chloroperbenzoic acid with 42 gave the epoxide 35.
  • the compound of formula A is protected for example by reaction with 1-(tert-butoxycarbonyl)-2-tert-butyl-3-methyl-4-imidazolidinone (BOC-ON).
  • BOC-ON 1-(tert-butoxycarbonyl)-2-tert-butyl-3-methyl-4-imidazolidinone
  • the reaction is conducted in an organic solvent, for example, chloroform over 15-45 minutes, preferably 30 minutes at about room temperature in the presence of an organic base, for example triethylamine.
  • an organic base for example triethylamine
  • the protected piperazine of formula (B) is reacted with a compound of Formula (C) made as shown in Scheme 30.
  • the two compounds are mixed in an inert solvent, for example a halogenated solvent, for example methylene chloride, optionally in the presence of a catalyst, for example ytterbium (M)trifluoromethanesulfonate.
  • a catalyst for example ytterbium (M)trifluoromethanesulfonate.
  • the reaction is conducted at about 0-30° C., preferably at about room temperature, for about 8-48 hours, preferably overnight.
  • the mixture is refluxed for a similar period of time in ethanol in the presence of triethylamine.
  • the product of formula (D) is isolated and purified by chromatography on silica gel.
  • the compound of formula (D) is then deprotected by reaction with a strong acid, for example trifluoroacetic acid, in an inert solvent, for example methylene chloride.
  • a strong acid for example trifluoroacetic acid
  • an inert solvent for example methylene chloride.
  • the reaction is conducted at about 0-30° C., preferably at about room temperature, for about 8-48 hours, preferably overnight.
  • the product of formula (E) is isolated by conventional means.
  • Compounds of Formula (I) may also be synthesized using a resin mediated procedure. Briefly, a compound of formula (E) and a compound of formula (F) are placed into a vial and diluted with an inert solvent, for example dichloroethane. A resin, for example polystyrene-diisopropylethylamine (PS-DEEA) resin, is added, and the vial shaken at about 60-120° C., preferably about 80° C., for about 6-12 hours, preferably overnight.
  • PS-DEEA polystyrene-diisopropylethylamine
  • a mixture of resins for example, PS-Isocyanate resin and PS-Trisamine resin are added, and the mixture shaken at about 10-25° C., preferably at about room temperature, and then maintained at about 60-120° C., preferably at about 80° C., for about6-12 hours, preferably overnight.
  • the contents of the vial are transferred into a frit-fitted syringe, filtered, washed with additional organic base, for example, dichloroethane repeatedly.
  • additional organic base for example, dichloroethane repeatedly.
  • concentration for example, by SpeedvacTM the crude mixture is purified and analyzed by standard means.
  • the compound of Formula (I) is isolated as a free base using standard methodology.
  • a compound of formula (C) is prepared conventionally by reaction of a compound of formula (a) with an epoxide of formula (b).
  • the two compounds are mixed in an inert solvent, preferably a ketone, for example acetone, in the presence of a tertiary organic base or an inorganic base, preferably potassium carbonate, at a temperature of about reflux, for about 8-48 hours overnight.
  • an inert solvent preferably a ketone, for example acetone
  • a tertiary organic base or an inorganic base preferably potassium carbonate
  • Chiral compounds of the formula (C) can be prepared in a similar manner by replacing compounds of the formula (b) with a chiral compound of formula (b), for example: (R)-( ⁇ )epichlorohydrin, (S)-(+)epichlorohydrin, (S)-4-bromo-1,2-epoxybutane, (R)-4-bromo-(1,2-epoxybutane), and the like.
  • a compound of formula (C) is dissolved in an inert solvent, for example methanol, and a catalyst, for example, 10% Pd/C, is added to the mixture.
  • the mixture is hydrogenated in a ParrTM shaker under pressure, for example at about 30 psi, until consumption of hydrogen ceases.
  • the compound of formula (d) is isolated conventionally, and preferably used without further purification.
  • the compound of formula (d) is reacted a compound of formula (e) in an inert solvent, for example methanol.
  • the reaction is conducted at about 25-60° C., preferably about 45° C., for about 4-24 hours, preferably about 12 hours.
  • the mixture is concentrated under reduced pressure and the residue is dissolved in an inert organic solvent, for example, dichloromethane.
  • a dehydrogenating agent for example dichlorodicyanoquinone (DDQ)
  • DDQ dichlorodicyanoquinone
  • the compound of formula (f) is isolated and purified using standard means, for example flash column chromatography.
  • the compound of formula (f) is dissolved in an organic solvent, for example dichloromethane.
  • an organic solvent for example dichloromethane.
  • a Lewis acid for example boron tribromide
  • the mixture is then diluted with additional organic solvent, for example dichloromethane and washed sequentially with a base, for example saturated sodium bicarbonate, followed by brine.
  • a base for example saturated sodium bicarbonate
  • the organic layer is separated, dried over MgSO 4 and filtered. After removal of solvent, formula (g) is purified using standard methods, for example flash chromatography.
  • a compound of formula (C) is prepared conventionally by reaction of a compound of formula (g) with an epoxide of formula (b).
  • the two compounds are mixed in an inert solvent, preferably a ketone, for example acetone, in the presence of a tertiary organic base or an inorganic base, preferably potassium carbonate, at a temperature of about reflux, for about 8-48 hours, preferably overnight.
  • an inert solvent preferably a ketone, for example acetone
  • a tertiary organic base or an inorganic base preferably potassium carbonate
  • the compound of formula (i) is reacted with a compound of formula (j) in a inert solvent, for example diethyl ether, in the presence of a base, for example, sodium bicarbonate.
  • a base for example, sodium bicarbonate.
  • the mixture is stirred at about ⁇ 10° C. to 10° C., preferably about 0° C., for about 1-6 hours, preferably about 2 hours, and for a further 0.5-2 hours, preferably 1 hour, at room temperature.
  • the organic layer is washed with an acid, for example, citric acid, and the compound of formula (F) separated and purified conventionally.
  • the acid addition salts of the compounds of this invention may be converted to the corresponding free base by treating with a suitable base, such as potassium carbonate or sodium hydroxide, typically in the presence of aqueous solvent, and at a temperature of between about 0 degrees C. and 100 degrees C.
  • a suitable base such as potassium carbonate or sodium hydroxide
  • the free base form is isolated by conventional means, such as extraction with an organic solvent.
  • Salts of the compounds of this invention may be interchanged by taking advantage of differential solubilities and volatilities, or by treating with the appropriately loaded ion exchange resin. This conversion is carried out at a temperature between about 0° C. and the boiling point of the solvent being used as the medium for the procedure.
  • Administration of the active compounds and salts described herein can be via any of the accepted modes of administration for therapeutic agents. These methods include oral, parenteral, transdermal, subcutaneous and other systemic modes. The preferred method of administration is oral, except in those cases where the subject is unable to ingest, by himself, any medication. In those instances it may be necessary to administer the composition parenterally.
  • compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages.
  • the compositions may include one or more conventional pharmaceutical excipients and at least one active compound of this invention or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.
  • the amount of active compound administered will, of course, be dependent on the subject being treated, the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. However, an effective dosage is in the range of 0.1-30 mg/kg/day, preferably 0.5-20 mg/kg/day. For an average 70 kg human, this would amount to 7-2100 mg per day, or preferably 35-1400 mg/day.
  • conventional non-toxic solid include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used.
  • the active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, for example, propylene glycol, as the carrier.
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc.
  • an active compound as defined above and optional pharmaceutical adjuvants in a excipient such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • a excipient such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like.
  • the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • wetting or emulsifying agents such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc.
  • compositions or formulation to be administered will, in any event, contain a quantity of the active compound(s), a therapeutically effective amount, i.e. in an amount effective to alleviate the symptoms of the subject being treated.
  • a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like.
  • Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like.
  • Such compositions may contain 10%-95% active ingredient, preferably 1-70%.
  • Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like.
  • the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
  • compositions of this invention can be administered orally in a sustained release dosage form using the compositions and/or methods disclosed in U.S. patent application Ser. No. 09/321,522, filed on May 27, 1999, the specification of which is incorporated herein by reference.
  • Compound 50 was prepared from the commercially available 6-methoxy-2-methyl-benzothiazole as described in partC-4 of Example 1.
  • Compound 53 was prepared in the manner of compound 3 substituting 2,6-dimethylpiperazine for piperazine in part A of Example 1.
  • Rat heart mitochondria were isolated by the method of Nedergard and Cannon (Methods in Enzymol. 55, 3, 1979).
  • Palmitoyl CoA oxidation The Palmityl CoA oxidation was carried out in a total volume of 100 micro liters containing the following agents: 110 mM KCl, 33 mM Tris buffer at pH 8, 2 mM KPi, 2 mM MgCl 2 , 0.1 mM EDTA, 14.7 microM defatted BSA, 0.5 mM malic acid, 13 mM camitine, 1 mM ADP, 52 micrograms of mitochondrial protein, and 16 microM 1-C14 palmitoyl CoA (Sp. Activity 60 mCi/mmole; 20 microCi/ml, using 5 microliters per assay).
  • the compounds of this invention were added in a DMSO solution at the following concentrations: 100 microM, and 50 microM.
  • a DMSO control was used. After 15 min at 30° C., the enzymatic reaction was centrifuged 20,000 g for 1 min), and 70 microliters of the supernatant was added to an activated reverse phase silicic acid column (approximately 0.5 ml of silicic acid). The column was eluted with 2 ml of water, and 0.5 ml of the eluent was used for scintillation counting to determine the amount of C 14 trapped as C 14 bicarbonate ion.
  • Metabolic Stability As a measure of metabolic stability the compounds of this invention were incubated with human liver S-9 microsomal fractions. After, 30 minutes at 37 C, the amount of parent drug remaining was determined using LC-mass spec. The response factors for each compound was determined by establishing a standard curve and using an internal standard during the analysis of the samples. An average of five experiments for percentage of ranolazine remaining at the 30 minute time point is 57%. The compounds of this invention were assayed as described in the protocol below and the percentage of parent remaining was divided by the average % of ranolazine remaining (57%) affording a metabolic stability factor. A compound with a stability number greater than 1.2 has a better stability than ranolazine in the liver S-9 assay. A compound with a stability number between 1.2 and 0.8 has an equivalent stability in the liver S-9 assay. A compound with a stability number less than 0.8 is less stable than ranolazine in the liver S-9 assay.
  • the purpose of this experiment is to compare the percentages remaining for compounds of this invention with the percentage remaining for ranolazine after 30 minutes of incubation with human liver S9 fractions.
  • Incubation mixtures were prepared as follows: TABLE 2 Volume per 0.25 mL of Incubation Final Component Mixture concentration 10 ⁇ M CVT 25 ⁇ L 10 ⁇ M compounds MgCl 2 25 ⁇ L 0.005 M NADPH 25 ⁇ L 0.002 M S9 25 ⁇ L 2 mg/mL Incubation Buffer 25 ⁇ L 0.05 M Water 125 ⁇ L —

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Novel compounds of the general formula:
Figure US20040192702A1-20040930-C00001
and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of diabetes, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

Description

  • This application is a continuation in part of US RCE Application No. 09/694,155 filed Apr. 9, 2002 which claims priority from U.S. patent application Ser. No. 09/694,155, filed Oct. 23, 2000.[0001]
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0002]
  • The present invention is concerned with piperazine derivatives, therapeutic dosage forms including one or more of the derivatives, and methods for treating diseases in mammals, and in particular, in a human in a therapy selected from the group including diabetes, protecting skeletal muscles against damage resulting from diabetes, trauma, protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction. [0003]
  • 2. Description of the Art [0004]
  • U.S. Pat. No. 4,567,264, the specification of which is incorporated herein by reference, discloses a class of substituted piperazine compounds that includes a compound known as ranolazine, (±)-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]-1-piperazineacetamide, and its pharmaceutically acceptable salts, and their use in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise-induced angina, and myocardial infarction. [0005]
  • U.S. Pat. No. 5,506,229, which is incorporated herein by reference, discloses the use of ranolazine and its pharmaceutically acceptable salts and esters for the treatment of tissues experiencing a physical or chemical insult, including cardioplegia, hypoxic or reperfusion injury to cardiac or skeletal muscle or brain tissue, and for use in transplants. In particular, ranolazine is particularly useful for treating arrhythmias, variant and exercise-induced angina, and myocardial infarction by partially inhibiting cardiac fatty acid oxidation. Conventional oral and parenteral ranolazine formulations are disclosed, including controlled release formulations. In particular, Example 7D of U.S. Pat. No. 5,506,229 describes a controlled release formulation in capsule form comprising microspheres of ranolazine and microcrystalline cellulose coated with release controlling polymers. [0006]
  • Despite the important discovery that ranolazine is a very useful cardiac therapeutic agent, there remains a need for compounds that are partial fatty acid oxidation inhibitors that have a half-life greater than ranolazine and that have activities as least similar to ranolazine. Several of such compounds are disclosed in U.S. patent application Ser. No. 09/694,155, filed Oct. 23, 2001. We have now discovered other compounds that are useful as partial inhibitors of oxidation including specific enantiomers and diastereoisomers, and also that such compounds are useful in the treatment of other disease states, including diabetes and atrial and ventricular arrhythmia. [0007]
    • SUMMARY OF THE INVENTION
  • This invention includes novel heteroaryl alkyl piperazine derivatives that are partial fatty acid oxidation inhibitors with good therapeutic half-lives. [0008]
  • This invention also includes novel substituted piperazine compounds that can be administered to a mammal to protect skeletal muscles against damage resulting from trauma, to protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction. [0009]
  • This invention includes a class of substituted piperazine compounds having the formula: [0010]
    Figure US20040192702A1-20040930-C00002
  • wherein m=1, 2, or 3; [0011]
  • q=NH, O, or S; [0012]
  • R[0013] 1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, and SO2R22;
  • R[0014] 6, R7 and R8 each independently selected from the group consisting of hydrogen and C1-3 alkyl;
  • R[0015] 9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen, CO2R20, CON(R20)2, C1-4 alkyl, and aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF3, CN, OR20, —N(R20)2, —CO2R20, —CON(R20)2 and aryl, wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl or R11 and R13 or R9 and R15 or R9 and R11 or R11 and R15 or R9 and R13 may join together to form a ring including from 1 to 3 carbon atoms;
  • R[0016] 17 is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, and SO2R22;
  • R[0017] 20 is selected from the group consisting of H, C1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono- or dialkylamino, alkyl, CN, —O—C1-6 alkyl, and CF3; and
  • R[0018] 22 is selected from the group consisting of C1-15 alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O—C1-6 alkyl, CF3, and heteroaryl.
  • Preferred compounds include: [0019]
  • N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide, 2-{4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethylphenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide,4-(3-{4-[(2,6-dimethylphenylcarbamoyl)-methyl]-piperazin-1-yl}-2-hydroxypropoxy)-1H-indole-2-carboxamide, 2-{4-[3-(benzothiazol-6-yloxy)2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethyl-phenyl)-acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-6-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-3,5-cisdimethyl-piperazine-1-yl}acetamide, 2-{4-[2-hydroxy-3-(2-methyl-berizothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-(4-hydroxy-phenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzoxazol-5-yloxy)-propyl)-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-7-yloxy)-propyl]-piperazin-1-ylacetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-2-oxo-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(4-trifluoromethyl-phenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinoxalin-2-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(pyridin-3-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-4-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-quinolin-7-yloxy)-propyl]-piperazin-1-yl}acetamide, 2-{4-[3-(benzothiazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[3-(benzoxazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide. [0020]
  • Other preferred compounds include: [0021]
  • N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,5-cis dimethylpiperazinyl}acetamide; [0022]
  • 2-{(3R)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0023]
  • 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl](3S)-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0024]
  • 2-{(3R)-4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0025]
  • 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0026]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,5-cis dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0027]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,5-cis dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0028]
  • (±)-N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}acetamide; [0029]
  • 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0030]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0031]
  • 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,3-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0032]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0033]
  • 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(4-methylphenyl)acetamide; [0034]
  • 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-[4-(trifluoromethyl)phenyl]acetamide; [0035]
  • 2-{(3R)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-6-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0036]
  • 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-6-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0037]
  • 2-{(3R)-4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-6-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0038]
  • 2-{(3S)-4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-6-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0039]
  • N-((1S)-1-(2-naphthyl)ethyl)-2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}acetamide; [0040]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3-phenylphenyl)acetamide; [0041]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol--yloxy)propyl]piperazinyl}-N-(4-phenoxyphenyl)acetamide; [0042]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3-phenoxyphenyl)acetamide; [0043]
  • 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(4-cyanophenyl)acetamide; [0044]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-phenylphenyl)acetamide; [0045]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-methylphenyl)acetamide; [0046]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-(4-chlorophenoxy)phenyl]acetamide; [0047]
  • 2-{4-[(2S)-3-(2-cyclohexylbenzothiazol-5-yloxy)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0048]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-(trifluoromethyl)phenyl]acetamide; [0049]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(4-phenoxyphenyl)acetamide; [0050]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-(trifluoromethyl)phenyl]acetamide; [0051]
  • 2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0052]
  • 2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[4-(trifluoromethyl)phenyl]acetamide; [0053]
  • 2-[4-((2S)-2-hydroxy-3-{2-[3-(trifluoromethyl)phenyl]benzoxazol-5-yloxy}propyl)piperazinyl]-N-(2,6-dimethylphenyl)acetamide; [0054]
  • 2-((3S)-4-{(2S)-3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide; [0055]
  • 2-((3R)-4-{(2S){3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide. [0056]
  • 2-((3R)-4-{(2R){3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide. [0057]
  • 2-((3S)-4-{(2R){3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide. [0058]
  • 2-((3S)-4-{(2S)-3-[2-(2-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide; [0059]
  • 2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0060]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(3-phenylphenyl)acetamide; [0061]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0062]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(2-phenylphenyl)acetamide; [0063]
  • 2-((3S)-4-{(2S)-3-[2-(2-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide; [0064]
  • 2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0065]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(3-phenylphenyl)acetamide; [0066]
  • 2-{4-[([0067] 2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide;
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(2-phenylphenyl)acetamide; [0068]
  • 2-(4-{(2S)-3-[2-(2-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-(2,6-dimethylphenyl)acetamide; [0069]
  • 2-[4-((2S)-2-hydroxy-3-{2-[2-(trifluoromethyl)phenyl]benzoxazol-5-yloxy}propyl)piperazinyl]-N-(2,6-dimethylphenyl)acetamide; [0070]
  • 2-{4-[(2S)-2-hydroxy-3-(2-propylbenzothiazol-5-yloxy)propyl]piper-azinyl}-N-(2,6-dimethylphenyl)acetamide; [0071]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0072]
  • 2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0073]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(3-phenoxyphenyl)acetamide; [0074]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(2-phenoxyphenyl)acetamide; [0075]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2-phenylphenyl)acetamide; [0076]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piper-azinyl}-N-(4-cyanophenyl)acetamide; [0077]
  • 2-(4-{(2S)-2-hydroxy-3-[2-(2-methyl(1,3-thiazol-4-yl))ethoxy]propyl}piperazinyl)-N-(2,6-dimethylphenyl)acetamide; [0078]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(4-phenylphenyl)acetamide; and [0079]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3-phenoxyphenyl)acetamide. [0080]
  • In yet another embodiment, this invention is a method for using one or more compounds of the invention to a mammal to treat a disease selected from the group consisting of diabetes, protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle, systemic diseases such as intermittent claudication, shock conditions, preserving donor tissue and organs used in transplants, and cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.[0081]
    • DETAILED DESCRIPTION OF THE INVENTION
  • A class of substituted piperazine compounds having the following formula: [0082]
    Figure US20040192702A1-20040930-C00003
  • wherein: [0083]
  • m=1, 2, or 3; [0084]
  • q=NH, O, or S; [0085]
  • R[0086] 1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, and SO2R22;
  • R[0087] 6, R7 and R8 each independently selected from the group consisting of hydrogen and C1-3 alkyl;
  • R[0088] 9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen, CO2R20, CON(R20)2, C1-4 alkyl, and aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF3, CN, OR20, N(R20)2, —CO2R20, —CON(R20)2 and aryl, wherein R9 and R10 may together form a carbonyl, or R11 and R12 may together form a carbonyl, or R13 and R14 may together form a carbonyl, or R15 and R16 may together form a carbonyl or R11 and R13 or R9 and R15 or R9 and R11 or R11 and R15 or R9 and R13 may join together to form a ring including from 1 to 3 carbon atoms;
  • R[0089] 17 is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, SO2R22, SO2N(R20)2, NR20CO2R22, NR20CON(R20)2, COR20, CO2R20, CON(R20)2, NR20SO2R22, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO2, CF3, CN, OR20, SR20, N(R20)2, S(O)R22, and SO2R22;
  • R[0090] 20 is selected from the group consisting of H, C1-15 alkyl, aryl, and heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono and dialkylamino, alkyl, CN, —O—C1-6 alkyl, and CF3; and
  • R[0091] 22 is selected from the group consisting of C1-15 alkyl, aryl, and heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, —O—C1-6 alkyl, CF3, and heteroaryl.
  • The following definitions apply to terms as used herein. [0092]
  • “Halo” or “Halogen”—alone or in combination means all halogens, that is, chloro (Cl), fluoro (F), bromo (Br), iodo (I). [0093]
  • “Hydroxyl” refers to the group —OH. [0094]
  • “Thiol” or “mercapto” refers to the group —SH. [0095]
  • “Alkyl”—alone or in combination means an alkane-derived radical containing from 1 to 20, preferably 1 to 15, carbon atoms (unless specifically defined). It is a straight chain alkyl, branched alkyl or cycloalkyl. Preferably, straight or branched alkyl groups containing from 1-15, more preferably 1 to 8, even more preferably 1-6, yet more preferably 1-4 and most preferably 1-2, carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl and the like. The term “lower alkyl” is used herein to describe the straight chain alkyl groups described immediately above. Preferably, cycloalkyl groups are monocyclic, bicyclic or tricyclic ring systems of 3-8, more preferably 3-6, ring members per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like. Alkyl also includes a straight chain or branched alkyl group that contains or is interrupted by a cycloalkyl portion. The straight chain or branched alkyl group is attached at any available point to produce a stable compound. Examples of this include, but are not limited to, 4-(isopropyl)-cyclohexylethyl or 2-methyl-cyclopropylpentyl. A substituted alkyl is a straight chain alkyl, branched alkyl, or cycloalkyl group defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like. [0096]
  • “Alkenyl”—alone or in combination means a straight, branched, or cyclic hydrocarbon containing 2-20, preferably 2-17, more preferably 2-10, even more preferably 2-8, most preferably 2 to 4 carbon atoms with at least one, preferably 1-3, more preferably 1-2, and most preferably one, carbon to carbon double bond. In the case of a cycloalkyl group, conjugation of more than one carbon to carbon double bond is not such as to confer aromaticity to the ring. Carbon to carbon double bonds may be either contained within a cycloalkyl portion, with the exception of cyclopropyl, or within a straight chain or branched portion. Examples of alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, cyclohexenyl, cyclohexenylalkyl and the like. A substituted alkenyl is the straight chain alkenyl, branched alkenyl or cycloalkenyl group defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, amino sulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, carboxy, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, or the like attached at any available point to produce a stable compound. [0097]
  • “Alkynyl”—alone or in combination means a straight or branched hydrocarbon containing 2-20, preferably 2-17, more preferably 2-10, even more preferably 2-8, most preferably 2-4, carbon atoms containing at least one, preferably one, carbon to carbon triple bond. Examples of alkynyl groups include ethynyl, propynyl, butynyl and the like. A substituted alkynyl refers to the straight chain alkynyl or branched alkynyl defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like attached at any available point to produce a stable compound. [0098]
  • “Alkyl alkenyl” refers to a group —R—CR′═CR′″R″″, where R is lower alkyl, or substituted lower alkyl, R′, R′″, R″″ may independently be hydrogen, halogen, lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined below. [0099]
  • “Alkyl alkynyl” refers to a groups —RC□OCR′ where R is lower alkyl or substituted lower alkyl, R′ is hydrogen, lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined below. [0100]
  • “Alkoxy” denotes the group —OR, where R is lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroalkyl, heteroarylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, or substituted cycloheteroalkyl as defined. [0101]
  • “Alkylthio” denotes the group —SR, —S(O)[0102] n=1−2—R, where R is lower alkyl, substituted lower alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl as defined herein.
  • “Acyl” denotes groups —C(O)R, where R is hydrogen, lower alkyl substituted lower alkyl, aryl, substituted aryl and the like as defined herein. [0103]
  • “Aryloxy” denotes groups —OAr, where Ar is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl group as defined herein. [0104]
  • “Amino” denotes the group NRR′, where R and R′ may independently by hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined herein or acyl. [0105]
  • “Amido” denotes the group —C(O)NRR′, where R and R′ may independently by hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, substituted hetaryl as defined herein. [0106]
  • “Carboxyl” denotes the group —C(O)OR, where R is hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, and substituted hetaryl as defined herein. [0107]
  • “Aryl”—alone or in combination means phenyl or naphthyl optionally carbocyclic fused with a cycloalkyl of preferably 5-7, more preferably 5-6, ring members and/or optionally substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like. [0108]
  • “Substituted aryl” refers to aryl optionally substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like. [0109]
  • “Heterocycle” refers to a saturated, unsaturated, or aromatic carbocyclic group having a single ring (e.g., morpholino, pyridyl or turyl) or multiple condensed rings (e.g., naphthpyridyl, quinoxalyl, quinolinyl, indolizinyl or benzo[b]thienyl) and having at least one hetero atom, such as N, O or S, within the ring, which can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like. [0110]
  • “Heteroaryl”—alone or in combination means a monocyclic aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing one or more, preferably 1-4, more preferably 1-3, even more preferably 1-2, heteroatoms independently selected from the group O, S, and N, and optionally substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable aromatic ring is retained. Examples of heteroaryl groups are pyridinyl, pyridazinyl, pyrazinyl, quinazolinyl, purinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazinyl, furanyl, benzofuryl, indolyl, benzothiazolyl, benzoxazolyl, and the like. A substituted heteroaryl contains a substituent attached at an available carbon or nitrogen to produce a stable compound. [0111]
  • “Heterocyclyl”—alone or in combination means a non-aromatic cycloalkyl group having from 5 to 10 atoms in which from 1 to 3 carbon atoms in the ring are replaced by heteroatoms of O, S or N, and are optionally benzo fused or fused heteroaryl of 5-6 ring members and/or are optionally substituted as in the case of cycloalkyl. Heterocycyl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. The point of attachment is at a carbon or nitrogen atom. Examples of heterocyclyl groups are tetrahydrofuranyl, dihydropyridinyl, piperidinyl, pyrrolidinyl, piperazinyl, dihydrobenzoflryl, dihydroindolyl, and the like. A substituted hetercyclyl contains a substituent nitrogen attached at an available carbon or nitrogen to produce a stable compound. [0112]
  • “Substituted heteroaryl” refers to a heterocycle optionally mono or poly substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like. [0113]
  • “Aralkyl” refers to the group —R—Ar where Ar is an aryl group and R is lower alkyl or substituted lower alkyl group. Aryl groups can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like. [0114]
  • “Heteroalkyl” refers to the group —R-Het where Het is a heterocycle group and R is a lower alkyl group. Heteroalkyl groups can optionally be unsubstituted or substituted with e.g., halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like. [0115]
  • “Heteroarylalkyl” refers to the group -R-HetAr where HetAr is an heteroaryl group and R lower alkyl or substituted lower alkyl. Heteroarylalkyl groups can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like. [0116]
  • “Cycloalkyl” refers to a divalent cyclic or polycyclic alkyl group containing 3 to 15 carbon atoms. [0117]
  • “Substituted cycloalkyl” refers to a cycloalkyl group comprising one or more substituents with, e.g., halogen, lower alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like. [0118]
  • “Cycloheteroalkyl” refers to a cycloalkyl group wherein one or more of the ring carbon atoms is replaced with a heteroatom (e.g., N, O, S or P). [0119]
  • “Substituted cycloheteroalkyl” refers to a cycloheteroalkyl group as herein defined which contains one or more substituents, such as halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like. [0120]
  • “Alkyl cycloalkyl” denotes the group —R-cycloalkyl where cycloalkyl is a cycloalkyl group and R is a lower alkyl or substituted lower alkyl. Cycloalkyl groups can optionally be unsubstituted or substituted with e.g. halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like. [0121]
  • “Alkyl cycloheteroalkyl” denotes the group —R-cycloheteroalkyl where R is a lower alkyl or substituted lower alkyl. Cycloheteroalkyl groups can optionally be unsubstituted or substituted with e.g. halogen, lower alkyl, lower alkoxy, alkylthio, amino, amido, carboxyl, acetylene, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like. [0122]
  • “Optional” and “optionally” mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “optional pharmaceutical excipients” indicates that a formulation so described may or may not include pharmaceutical excipients other than those specifically stated to be present, and that the formulation so described includes instances in which the optional excipients are present and instances in which they are not. [0123]
  • “Treating” and “treatment” refer to any treatment of a disease in a mammal, particularly a human, and include: [0124]
  • (i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; [0125]
  • (ii) inhibiting the disease, i.e., arresting its development; or [0126]
  • (iii) relieving the disease, i.e., causing regression of the disease. [0127]
  • All of the aforementioned embodiments include the pharmaceutically acceptable acid addition salts thereof, particularly the mono- and dihydrochlorides, and mixtures thereof. [0128]
  • The compounds having the general formula Ia (q=O) or Ic (q=S) can be prepared as outlined in Schemes 1-5. A general synthesis of the compounds of this invention is outlined in Scheme 1. Compound IV can be prepared by N-acylation of substituted aniline II with 2-substituted chloroacetylchloride III. Compound II is available commercially or readily prepared through reduction of the corresponding nitrobenzene derivative (acid/SnCl[0129] 2 or catalytic hydrogenation, see Advanced Organic Chemistry, Ed. J. March, (1992) A. Wiley-Interscience). Some examples of commercially available substituted anilines corresponding to general structure II include 2,6-dimethylaniline, 2,3-dimethylaniline, 2-methylaniline, 4-methylaniline, 4-methylaniline, 2,4-dichloroaniline, 3,4-dichloroaniline, 2,5-dichloroaniline, 2,4-dichloroaniline, 2-chloroaniline, 3-chloroaniline, 2,6-difluoroaniline, 2,5-difluoroaniline, 3,4-difluoroaniline, 2-fluoroaniline, 4-fluoroaniline, 3-fluoroaniline, 2-fluoro-6-chloroaniline, 4-fluoro-3-chloroaniline, 4-acetoxyaniline.
  • The term “compound of Formula I” is intended to encompass the compounds of the invention as disclosed, and the pharmaceutically acceptable salts, pharmaceutically acceptable esters, prodrugs, hydrates, and polymorphs of such compounds. [0130]
  • Additionally, the compounds of the invention may possess one or more asymmetric centers, and can be produced as a racemic mixture or as individual enantiomers or diastereoisomers. The number of stereoisomers present in any given compound of Formula I depends upon the number of asymmetric centers present (there are 2n stereoisomers possible where n is the number of asymmetric centers). The individual stereoisomers may be obtained by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolution of the compound of Formula I by conventional means. The individual stereoisomers (including individual enantiomers and diastereoisomers) as well as racemic and non-racemic mixtures of stereoisomers are encompassed within the scope of the present invention, all of which are intended to be depicted by the structures of this specification unless otherwise specifically indicated. [0131]
  • “Isomers” are different compounds that have the same molecular formula. [0132]
  • “Stereoisomers” are isomers that differ only in the way the atoms are arranged in space. [0133]
  • “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term “(±)” is used to designate a racemic mixture where appropriate. [0134]
  • “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. [0135]
  • The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog RS system. When the compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown are designated (+) or (−) depending on the direction (dextro- or laevorotary) which they rotate the plane of polarized light at the wavelength of the sodium D line. [0136]
    Figure US20040192702A1-20040930-C00004
  • Compound VI can be obtained by reacting compound IV with N-protected substituted piperazine V through warming in an appropriate solvent (e.g. DMF, EtOH). Protection of the nitrogen of compound V is only required when it is useful to control the regiochemistry of the addition of Compound V with compound IV. In some cases, compound V can be obtained from commercial resources. Examples of commercially available compounds corresponding to general structure V include 2-methylpiperazine, 2,5-dimethylpiprazine, 2,6-dimethylpiperazine, 2,3,5,6-tetramethylpiperazine, piperazine-2-carboxylic acid, perhydroquinoxaline, 2-aminomethyl-6-methylpiperazine, 2-aminomethylpiperazine, 2-(o-chlorophenyl)piperazine, and 2-(m-chlorophenyl)piperazine. Deprotection of compound VI can be accomplished using the standard conditions (e.g. for Boc group use TFA, for CBZ and benzyl use hydrogenation). Compound Ia or Ic can be prepared by reacting compound VII with epoxide VIII through warming in an appropriate solvent (ethanol, DMF, CHCl[0137] 2, THF) or by stirring at room temperature in the presence of a lanthamide (III) Lewis acid (Chini, M et al., Tetrahedron Lett., 35: 433-36 (1994).
    Figure US20040192702A1-20040930-C00005
  • Epoxide VIII (where m=1, 2, or 3) can be prepared as outlined in Scheme 2. Heating substituted phenol, or thiophenol IX with epichlorohydrin, epibromohydrin, or 4-bromo-1,2-epoxybutane and potassium carbonate in acetone or sodium hydride in DMF can afford epoxide VIII. Compound IX can be obtained from commercial resources. Examples of commercially available compounds corresponding to structure IX include 2-methyl-5-hydroxybenzothiazole, 2-hydroxybenzothiazole, 8-hydroxyquinolidine, 6-hydroxyquinoline, 4-hydroxyquinoline, 5-hydroxyisoquinoline, 3-hydroxypyridine, 2-quinoxalinol, and 4-(imidazol-1-yl)phenol. In some cases compound VIII can be obtained from commercial sources. Examples of commercially available compounds corresponding to general structure VIII include 4-glycidyloxy-2-indolecarboxamide. [0138]
  • Compounds of the formula (VIII) with chiral substituents can be prepared in the same manner as shown in Scheme 2. [0139]
  • Compound IX can in turn be prepared by the deprotection of the corresponding methyl or benzyl ethers (X) using Lewis acids as shown in Scheme 3 (BBr[0140] 3, BF3, etc.—see Advanced Organic Chemistry, Ed. J. March (1992) A. Wiley Intersciences, p 434). Benzyl ethers can also be deprotected by refluxing with palladium hydroxide in ethanol/cyclohexene (see Catalytic hydrogenation over platinum metals, P. N. Rylander, Academic Press, New York, N.Y., (1976) p 464). Commercially available methyl ethers include 6-methoxy-2-methyl-benzothiazole.
    Figure US20040192702A1-20040930-C00006
  • Compound IX can also be prepared by the diazotization of the corresponding amino compounds (XI) as shown in Scheme 4 (Boggust, W. A and Cocker, W. J. Chem. Soc. 1949, 355). Commercially available amines include 6-amino-benzothiazole. [0141]
    Figure US20040192702A1-20040930-C00007
  • The 6, 5 fused ring system of compound X can be prepared by the cyclization of commercially available ethers of 2-aminophenols, 2-aminothiophenols, or 2-aminoanilines (XII) with orthoesters (XIII) (Musser, J. H. et al., J. Med. Chem. 1985, 28, 1255-1259) or imidates (XIV) (Gregory, G. I. Et al., J. Chem. Soc. Perkin Trans. 1, 1973, 47-51) as shown in Scheme 5 and 6 respectively. Commercially available, ethers of aminophenols include 4-methoxy-2-aminophenol, orthoesters include trimethyl orthoformate and trimethyl orthoacetate, imidates include ethyl acetimidate hydrochloride, and ethyl benzimidate hydrochloride. [0142]
    Figure US20040192702A1-20040930-C00008
    Figure US20040192702A1-20040930-C00009
  • The thiophenol analog of compound XII can be prepared from the commercially available compound XV by reacting with sodium disulfide hydrate followed by reduction using tin and hydrochloric acid ( Dannley, R. L. and Zazaris, D. A; Can. J. Chem. 1965, 43, 2610-2612) as shown in Scheme 7. Commercially available nitro compounds include 3-nitro-4-chloroanisole. [0143]
    Figure US20040192702A1-20040930-C00010
  • Imidate XIV can be prepared by bubbling HCl gas through an alcoholic solution of the commercially available nitrites XVI as shown in Scheme 8. Commercially available nitrites include, benzonitrile, 4-trifluoromethylbenzonitrile and 3-trifluoromethylbenzonitrile. [0144]
    Figure US20040192702A1-20040930-C00011
  • Sulfur containing 6,5 fused ring system of compound X can also be prepared from the commercially available ethers of anilines XVII (Stevens, M. F. G. et al, J. Med. Chem. 1994, 37, 1689-1695) as shown in Scheme 9. Thioamide XX can be obtained by the reaction of Lawesson's reagent with amide XIX which in turn can be prepared by the reaction of compound XVII with compound XVIII. Cyclization of XX with potassium ferrocyanide under basic conditions can afford compound XXI. Commercially available ethers of anilines include benzyloxyanilines and anisidines. [0145]
    Figure US20040192702A1-20040930-C00012
  • A general synthesis of the compound XXV of this invention is outlined in Scheme 10. Compound XXIV can be prepared by the deprotection of compound XXIII using the standard conditions (e. g. for BOC group use TFA, for CBZ and benzyl use hydrogenation). Compound XXIII in turn can be prepared by the reaction of the commercially available protected monoketopiperazine analog compound XXII with compound IV and sodium hydride in an appropriate solvent (DMF, THF). An example of the commercially available monoketopiperazines include 4-benzyloxycarbonylpiperazine-2-one. [0146]
    Figure US20040192702A1-20040930-C00013
  • A general synthesis of the compound Ib (q=NH) of this invention is outlined in Schemes 11 and 12. Compound XXVII can be prepared by refluxing compound VII with the epoxide XXVI in a suitable solvent (ethanol, THF). Deprotection of compound XXVII can be accomplished by using standard conditions (e. g. for BOC group use TFA; for CBZ use hydrogenation or Pd(OH)[0147] 2). Compound Ib can be prepared by refluxing compound XXVIII with compound XXIX in a suitable solvent (ethanol, THF). Commercially available compound XXIX includes 2-chlorobenzothiazole, 2-chlorobenzoxazole, 2-chloropyridine, 2-chloropyrimidine, 2-chloro-4-(trifluoromethyl)pyrimidine, and chloropyrazine.
    Figure US20040192702A1-20040930-C00014
  • Epoxide XXVI in turn can be prepared as shown in Scheme 12. Commercially available compound XXX can be protected using the standard conditions (for BOC protection use BOC anhydride; for CBZ protection use CBZ-Cl). Compound XXV can be prepared by the reaction of compound XXXI using m-chloroperbenzoic acid in a suitable solvent (e. g. dichloromethane). An example of a commercially available compound XXX includes by is not limited to allylamine. [0148]
    Figure US20040192702A1-20040930-C00015
  • Compound V can be prepared as described in Scheme 13. Alkylation of compound XXXII with alkyl halides using t-BuLi as base can afford compound XXXIII as described by Pohlman et. al. (J. Org. Chem, 1997, 62, 1016-1022). Reduction of XXXIV using diborane can afford the N-benzyl protected version of compound V after N-Boc deprotection with trifluoroacetic acid (TFA) [for the diborane reduction see Jacobson et. al, J. Med. Chem, 1999, 42, 1123-1144]. [0149]
  • Compounds of the formula (5) with chiral substituents can be prepared in the same manner as shown in Scheme 13. [0150]
    Figure US20040192702A1-20040930-C00016
  • Compound V can also be prepared through standard coupling (eg. EDC or PyBroP) of D or L amino acids and standard deprotection as outlined in Scheme 14 (Cledera, P. et al. Tetrahedron, 1998 p. 12349-12360; Smith, R. A. et al Bioorg. Med. Chem. Lett. 1998, p. 2369-2374). Reduction of the diketopiperazine XXXVII with diborane can afford the N-benzyl protected version of compound V. [0151]
    Figure US20040192702A1-20040930-C00017
  • Compound V can also be prepared as described in Scheme 15. Bromination of aldehydes XXXVIII followed by the reaction with ethylene diamine can afford the imine XLI. Catalytic hydrogenation of compound XLI can afford compound V (Bogeso, K. P., et al, J. Med. Chem. 1995, 38, p 4380-4392). Commercially available aldehydes include isobutyraldehyde. [0152]
    Figure US20040192702A1-20040930-C00018
  • Compound V also includes the bicyclic homologs of piperazine (1S,4S)-(+)-2,5-diazabicyclo[2.2.1]heptane 83, 3,8-diazabicyclo[3.2.1]octane 84, and 2,5-diazabicyclo[2.2.2]octane 85. [0153]
    Figure US20040192702A1-20040930-C00019
  • Commercially available bicyclic analogs include (1S,4S)-(+)-2,5-diazabicyclo[2.2.1]heptane 83. Compounds 84, 85, and the (1R,4R) isomer of 83 can be prepared by published procedures (for 84 and 85—see Sturm, P. A et al, J. Med. Chem. 1974, 17, 481-487; for 83 see—Barish, T. F. and Fox, D. E. J. Org. Chem., 1990, 55, 1684-1687). [0154]
  • Specific examples of the preparation of compounds corresponding to the general schemes described above are disclosed in Scheme 16-29 of the Examples which further illustrate alternative methods for preparing compounds of this invention. In particular, 2,6-methylaniline was acylated with 2-chloroacetyl chloride 2 using saturated bicarbonate and ether (1:1) as base and co-solvent, respectively to afford the chloroacetamide derivative 3. Further reaction of compound 3 with piperazine afforded compound 5 through warming in ethanol. Reaction of compound 5 with epoxide 6 by warming both components in ethanol at reflux afforded piperazine derivative 7 as illustrated in Scheme 16. Compound 6 was prepared by warming epichlorohydrin with the phenol 8 in acetone in the presence of K[0155] 2CO3 as described in Scheme 17.
    Figure US20040192702A1-20040930-C00020
    Figure US20040192702A1-20040930-C00021
  • The benzoxazole derivative 8 was prepared by the deprotection of compound 13 as shown in Scheme 18. Compound 10 was prepared by condensation of 2-amino-4-methoxyphenol 12. Compound 12 was obtained by the catalytic hydrogenation of the commercially available 4-methoxy-2-nitrophenol 11, and the benzimidate derivative 13 as shown in Scheme 19. Compound 13 was obtained from 3-trifluoromethylbenzonitrile 14 using a Pinner reaction (ethanol/anhydrous HCl). [0156]
    Figure US20040192702A1-20040930-C00022
    Figure US20040192702A1-20040930-C00023
    Figure US20040192702A1-20040930-C00024
  • Synthesis of the key intermediates that were used in the preparation of the compounds described in this invention are shown in Scheme 21-25. Compound 16 was prepared by the diazotization of the commercially available 6-aminobenzothiazole as shown in scheme 21. [0157]
    Figure US20040192702A1-20040930-C00025
  • Compound 19 was prepared by condensation of compound 12 with trimethyl orthoacetate 18 as shown in Scheme 22. [0158]
    Figure US20040192702A1-20040930-C00026
  • Compound 22 can be prepared by the reduction of compound 21 with tin and hydrochloric acid as shown in Scheme 23. Compound 21 was synthesized by reacting compound 20 with sodium disulfide hydrate. [0159]
    Figure US20040192702A1-20040930-C00027
  • Compound 26 was prepared by the reaction of compound 25 with Lawesson's reagent as shown in Scheme 24. Compound 25 was prepared by the reaction of the aniline 23 with benzoyl chloride 24. Cyclization of the thioamide 26 with potassium ferrocyanide in aqueous sodium hydroxide gave a mixture of compounds 27 and 28. Compounds 27 and 28 were separated by column chromatography. [0160]
    Figure US20040192702A1-20040930-C00028
  • Debenzylation of compound 27 was carried out as shown in Scheme 25 by transfer hydrogenolysis using Pearlmann's catalyst in ethanol/cyclohexene. [0161]
    Figure US20040192702A1-20040930-C00029
  • Synthesis of compound 34 of this invention is described in Scheme 26. The amide 3 was prepared as described in Scheme 16. Reaction of 3 with the anion of the monoketopiperazine 30 formed through treatment with sodium hydride in DMF gave compound 31. Compound 34 was obtained through warming compound 32 with the epoxide 33 in ethanol. Compound 32 was prepared by the deprotection of compound 31 by catalytic dehydrogenation. Epoxide 33 was prepared in the same manner as compound 6 described in Scheme 17. [0162]
    Figure US20040192702A1-20040930-C00030
  • Synthesis of a specific compound 39 of this invention is described in Scheme 27. The synthesis of compound 5 was described previously (Scheme 16). Warming compound 5 to reflux with the epoxide 35 in ethanol gave compound 36. Deprotection of 36 by treatment with palladium hydroxide in ethanol/cyclohexene under reflux conditions gave the amine 37. The final compound 39 was prepared by reacting 37 with 2-chlorobenzothiazole in ethanol and triethylamine. [0163]
    Figure US20040192702A1-20040930-C00031
  • Epoxide 35 was synthesized as described in Scheme 28. Allylamine 40 was reacted with benzyl chloroformate in dichloromethane to afford compound 42. Reaction of m-chloroperbenzoic acid with 42 gave the epoxide 35. [0164]
    Figure US20040192702A1-20040930-C00032
  • Compounds of Formula I can be synthesized as shown in Scheme 29 as follows. [0165]
    Figure US20040192702A1-20040930-C00033
  • Step 1.Synthesis of the Compound of Formula (B). [0166]
  • The compound of formula A is protected for example by reaction with 1-(tert-butoxycarbonyl)-2-tert-butyl-3-methyl-4-imidazolidinone (BOC-ON). The reaction is conducted in an organic solvent, for example, chloroform over 15-45 minutes, preferably 30 minutes at about room temperature in the presence of an organic base, for example triethylamine. When the reaction is substantially complete, the product of formula (D) is isolated by conventional means, for example, by column chromatography. [0167]
  • Step 2.Synthesis of the Compound of Formula (D). [0168]
  • The protected piperazine of formula (B) is reacted with a compound of Formula (C) made as shown in Scheme 30. In general, the two compounds are mixed in an inert solvent, for example a halogenated solvent, for example methylene chloride, optionally in the presence of a catalyst, for example ytterbium (M)trifluoromethanesulfonate. The reaction is conducted at about 0-30° C., preferably at about room temperature, for about 8-48 hours, preferably overnight. In the absence of a catalyst, the mixture is refluxed for a similar period of time in ethanol in the presence of triethylamine. When the reaction is substantially complete, the product of formula (D) is isolated and purified by chromatography on silica gel. [0169]
  • Step 3—Preparation of Formula (E) [0170]
  • The compound of formula (D) is then deprotected by reaction with a strong acid, for example trifluoroacetic acid, in an inert solvent, for example methylene chloride. The reaction is conducted at about 0-30° C., preferably at about room temperature, for about 8-48 hours, preferably overnight. When the reaction is substantially complete, the product of formula (E) is isolated by conventional means. [0171]
  • Step 4—Synthesis of Formula I [0172]
  • Compounds of Formula (I) may also be synthesized using a resin mediated procedure. Briefly, a compound of formula (E) and a compound of formula (F) are placed into a vial and diluted with an inert solvent, for example dichloroethane. A resin, for example polystyrene-diisopropylethylamine (PS-DEEA) resin, is added, and the vial shaken at about 60-120° C., preferably about 80° C., for about 6-12 hours, preferably overnight. After cooling to room temperature, a mixture of resins, for example, PS-Isocyanate resin and PS-Trisamine resin are added, and the mixture shaken at about 10-25° C., preferably at about room temperature, and then maintained at about 60-120° C., preferably at about 80° C., for about6-12 hours, preferably overnight. After cooling to room temperature, the contents of the vial are transferred into a frit-fitted syringe, filtered, washed with additional organic base, for example, dichloroethane repeatedly. After concentration, for example, by Speedvac™ the crude mixture is purified and analyzed by standard means. The compound of Formula (I) is isolated as a free base using standard methodology. [0173]
  • The above synthesis may be used to prepare racemic or chiral compounds of Formula I. [0174]
  • The compounds of formula C are prepared as shown in Scheme 30. [0175]
    Figure US20040192702A1-20040930-C00034
  • Preparation of the Compounds of Formula (C) [0176]
  • A compound of formula (C) is prepared conventionally by reaction of a compound of formula (a) with an epoxide of formula (b). In general, the two compounds are mixed in an inert solvent, preferably a ketone, for example acetone, in the presence of a tertiary organic base or an inorganic base, preferably potassium carbonate, at a temperature of about reflux, for about 8-48 hours overnight. When the reaction is substantially complete, the product of formula (C) is isolated by conventional means, for example by chromatography of the residual silica gel, or by crystallization. [0177]
  • Chiral compounds of the formula (C) can be prepared in a similar manner by replacing compounds of the formula (b) with a chiral compound of formula (b), for example: (R)-(−)epichlorohydrin, (S)-(+)epichlorohydrin, (S)-4-bromo-1,2-epoxybutane, (R)-4-bromo-(1,2-epoxybutane), and the like. [0178]
  • The synthesis of a compound of formula (C) where R[0179] 17 is benzoxazole is shown in Scheme 31 below.
    Figure US20040192702A1-20040930-C00035
  • Step 1.Synthesis of the Compound of Formula (d) [0180]
  • A compound of formula (C) is dissolved in an inert solvent, for example methanol, and a catalyst, for example, 10% Pd/C, is added to the mixture. The mixture is hydrogenated in a Parr™ shaker under pressure, for example at about 30 psi, until consumption of hydrogen ceases. The compound of formula (d) is isolated conventionally, and preferably used without further purification. [0181]
  • Step 2.Synthesis of Formula (f) [0182]
  • The compound of formula (d) is reacted a compound of formula (e) in an inert solvent, for example methanol. The reaction is conducted at about 25-60° C., preferably about 45° C., for about 4-24 hours, preferably about 12 hours. The mixture is concentrated under reduced pressure and the residue is dissolved in an inert organic solvent, for example, dichloromethane. To the solution is added a dehydrogenating agent, for example dichlorodicyanoquinone (DDQ), and the mixture is allowed to stir at about 10 to 25° C., preferably about room temperature, for about 15 minutes to 2 hours, preferably about 30 minutes. The compound of formula (f) is isolated and purified using standard means, for example flash column chromatography. [0183]
  • Step 3.Synthesis of Formula (g) [0184]
  • The compound of formula (f) is dissolved in an organic solvent, for example dichloromethane. To the solution is added a Lewis acid, for example boron tribromide, and the mixture is allowed to stir at 10 to 25° C., preferably at about room temperature, for about 24-72 hours, preferably 48 hours. The mixture is then diluted with additional organic solvent, for example dichloromethane and washed sequentially with a base, for example saturated sodium bicarbonate, followed by brine. The organic layer is separated, dried over MgSO[0185] 4 and filtered. After removal of solvent, formula (g) is purified using standard methods, for example flash chromatography.
  • Step. 4.Synthesis of Formula (C) [0186]
  • A compound of formula (C) is prepared conventionally by reaction of a compound of formula (g) with an epoxide of formula (b). In general, the two compounds are mixed in an inert solvent, preferably a ketone, for example acetone, in the presence of a tertiary organic base or an inorganic base, preferably potassium carbonate, at a temperature of about reflux, for about 8-48 hours, preferably overnight. When the reaction is substantially complete, the product of formula (C) is isolated by conventional means, for example by chromatography on silica gel. Alternatively, after filtration the product can be crystallized from the filtrate. [0187]
  • Preparation of a compound of formula (F) is shown in Scheme 32. [0188]
    Figure US20040192702A1-20040930-C00036
  • The compound of formula (i) is reacted with a compound of formula (j) in a inert solvent, for example diethyl ether, in the presence of a base, for example, sodium bicarbonate. The mixture is stirred at about −10° C. to 10° C., preferably about 0° C., for about 1-6 hours, preferably about 2 hours, and for a further 0.5-2 hours, preferably 1 hour, at room temperature. The organic layer is washed with an acid, for example, citric acid, and the compound of formula (F) separated and purified conventionally. [0189]
  • The acid addition salts of the compounds of this invention may be converted to the corresponding free base by treating with a suitable base, such as potassium carbonate or sodium hydroxide, typically in the presence of aqueous solvent, and at a temperature of between about 0 degrees C. and 100 degrees C. The free base form is isolated by conventional means, such as extraction with an organic solvent. [0190]
  • Salts of the compounds of this invention may be interchanged by taking advantage of differential solubilities and volatilities, or by treating with the appropriately loaded ion exchange resin. This conversion is carried out at a temperature between about 0° C. and the boiling point of the solvent being used as the medium for the procedure. Administration of the active compounds and salts described herein can be via any of the accepted modes of administration for therapeutic agents. These methods include oral, parenteral, transdermal, subcutaneous and other systemic modes. The preferred method of administration is oral, except in those cases where the subject is unable to ingest, by himself, any medication. In those instances it may be necessary to administer the composition parenterally. [0191]
  • Depending on the intended mode, the compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages. The compositions may include one or more conventional pharmaceutical excipients and at least one active compound of this invention or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc. [0192]
  • The amount of active compound administered will, of course, be dependent on the subject being treated, the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. However, an effective dosage is in the range of 0.1-30 mg/kg/day, preferably 0.5-20 mg/kg/day. For an average 70 kg human, this would amount to 7-2100 mg per day, or preferably 35-1400 mg/day. [0193]
  • Since many of the effects of the compounds herein (protect skeletal muscles against damage resulting from trauma; protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication; treat shock conditions; preserve donor tissue and organs used in transplants; and treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, exercise induced angina, congestive heart disease, and myocardial infarction) are achieved through a similar mechanism (partial fatty acid oxidation inhibition) dosages (and forms of administration) are all generally within the same general and preferred ranges for all these utilities. [0194]
  • For solid compositions, conventional non-toxic solid include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, for example, propylene glycol, as the carrier. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15[0195] th Edition, 1975. The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s), a therapeutically effective amount, i.e. in an amount effective to alleviate the symptoms of the subject being treated. For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain 10%-95% active ingredient, preferably 1-70%.
  • Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc. [0196]
  • A more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, e.g., U.S. Pat. No. 3,710,795, which is incorporated herein by reference. In another recent approach, the compositions of this invention can be administered orally in a sustained release dosage form using the compositions and/or methods disclosed in U.S. patent application Ser. No. 09/321,522, filed on May 27, 1999, the specification of which is incorporated herein by reference. [0197]
  • It is within the scope of this invention to administer one or more compounds of this invention to a mammal, and preferably to a human by other known routes of pharmaceutical dosage form administration including, but not limited to by bolus, intravenously, transdermally, through inhalation, sub-cutaneously, or any other therapeutic agent administration method or route know to one skilled in the art. [0198]
  • The following Examples are representative of the invention, but are not to be construed as limiting the scope of the claims. [0199]
    • EXAMPLE 1 N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide (7)
  • [0200]
    Figure US20040192702A1-20040930-C00037
  • Part A [0201]
  • Synthesis of N-(2,6-dimethylphenyl)-2-chloroacetamide (3) [0202]
  • 2,6-dimethylaniline (9.8 g, 81.2 mmol) was dissolved in ether (100 mL) and saturated aqueous NaHCO[0203] 3 (100 mL) and the reaction mixture was cooled in an ice/water bath. To the cold solution was added chloroacetyl chloride 2 (9.17 g, 81.2 mmol) dropwise over a period of 2 h. The mixture was allowed to warm to RT over 14 h. The mixture was extracted with ethyl acetate (3×50). The combined organic layers were dried over MgSO4, filtered, and concentrated. The residue was triturated in ether and filtered to afford compound 3 as a white solid.
  • Part B [0204]
  • Synthesis of N-(2,6-dimethylphenyl)-piperazin-1-yl-acetamide (5) [0205]
  • To a solution of compound 3 (5 g, 25.2 mmol) in ethanol (100 mL) was added piperazine 4 (2.1 g, 25.0 mmol) and N,N-diisopropylethylamine (3.2 g, 25.2 mnol). The reaction mixture was refluxed for 24 h. The mixture was concentrated in vacuo and the residue was purified by column chromatography (10:1 DCM:MeOH) to afford compound 5. [0206]
  • Part C [0207]
  • Synthesis of 5-(oxiran-2-yl-methoxy)-2-[(3-trifluoromethyl)phenyl]benzoxazole (6) [0208]
  • 1.Synthesis of 2-amino-4-methoxyphenol (12) [0209]
  • A solution of 4-methoxy-2-nitrophenol 11 (10 g, 59.1 mmol) and Pd/C (1.0 g) in methanol (100 ml) was placed on a Parr shaker under H[0210] 2 (50 psi) for 60 minutes. The reaction mixture was filtered through Celite 521 and the filter cake washed with MeOH. The filtrate was evaporated (in vacuo), to yield compound 12 as a tan solid.
  • 2.Synthesis of 3-trifluoromethyl-benzimidic acid ethyl ester hydrochloride (13) [0211]
  • To a solution of α,α, α,-trifluoromethyl-m-tolunitrile 14 (1 g, 5.84 mmol) in EtOH (10 mL, anhydrous) was bubbled HCl (gas, anhydrous) for 10 minutes and the solution was stirred overnight. The solvent was evaporated to yield compound 13 as a white solid. The resulting solid was used in the next step without purification. [0212]
  • 3.Synthesis of 5-methoxy-2-(3-trifluoromethylphenyl)-benzoxazole (10) [0213]
  • A solution of compound 13 and compound 12 (850 mg, 6.13 mmol) in THF (10 mL) was heated to reflux and allowed to stir overnight. The reaction mixture was allowed to cool and the THF evaporated (in vacuo). The residue was dissolved in ethyl acetate and washed with water. The organic layer was dried over MgSO[0214] 4 and treated with activated carbon Norit A. The mixture was filtered through Celite 521, and evaporated (in vacuo) and the residue was purified using column chromatography (20% Ethyl acetate/hexanes) to afford compound 10 as a light yellow solid.
  • 4.Synthesis of 2-[(3-trifluoromethyl)phenyl]benzoxazol-5-ol (8) [0215]
  • To a solution of compound 10 (200 mg, 0.68 mmol) in CH[0216] 2Cl2 (5 mL) was added BBr3 (1M in CH2Cl2, 1 mL, 1 mmol) dropwise. The resulting solution was allowed to stir for 48 h. The solvent was removed by evaporation (in vacuo) and the residue was dissolved in ethyl acetate and washed with saturated NaHCO3. The organic layer was dried over MgSO4 and evaporated (in vacuo). The residue was purified using column chromatography (30% ethyl acetate/hexanes) to yield compound 8 as a white solid.
  • 5.Synthesis of 5-(oxiran-2-yl-methoxy)-2-[(3-trifluoromethyl)phenyl]-benzoxazole (6) [0217]
  • To a suspension of NaH (7 mg, 60% dispersion in oil, 0.18 mmol) in DMF (2 mL, anhydrous) was added a solution of compound 8 (54 mg, 0.19 mmol) in DMF (2 mL, anhydrous) dropwise. The solution was allowed to stir for 15 minutes. To the above solution epichlorohydrin (50□L, 0.63 mmol) was added and the resulting solution was allowed to stir overnight. The solvent was evaporated (in vacuo) and the residue dissolved in water and extracted with ethyl acetate. The organic layers were combined, dried over MgSO[0218] 4 and evaporated to yield compound 6 as a clear oil.
  • Part D [0219]
  • Synthesis N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide (7) [0220]
  • A solution of compound 5 (183 mg, 0.73 mmol) and compound 6 in EtOH (2 mL) and triethylamine (0.2 mL) was heated to 90° C. and allowed to stir overnight. The reaction mixture was allowed to cool and the solvent evaporated (in vacuo) to yield an oil. The oil was purified by prep TLC (5/0.5/94.5 MeOH/NH[0221] 4OH/CH2Cl2) to yield compound 7 as a white Solid: Mass Spectrum (MH+)=583.4
    • EXAMPLE 2 2-{4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethylphenyl)acetamide (43)
  • [0222]
    Figure US20040192702A1-20040930-C00038
  • Synthesis of 2-(oxiran-2-ylmethoxy)benzothiazole (44) [0223]
    Figure US20040192702A1-20040930-C00039
  • Compound 44 was prepared in the manner of compound 6 substituting 2-hydroxy-benzothiazole for compound 8 in partC-5 of Example 1. [0224]
  • Compound 43 was prepared in the manner of compound 7 substituting compound 44 for compound 6 in part D of compound 7: Mass Spectrum (MH[0225] +)=455.3.
    • EXAMPLE 3 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (45)
  • [0226]
    Figure US20040192702A1-20040930-C00040
  • Synthesis of 2-methyl-5-(oxiran-2-ylmethoxy)benzothiazole (33) [0227]
  • Compound 33 was prepared in the manner of compound 6 substituting 2-methyl-benzothiazol-5-ol [0228]
    Figure US20040192702A1-20040930-C00041
  • for compound 8 in partC-5 of Example 1. [0229]
  • Compound 45 was prepared in the manner of compound 7 substituting compound 33 for compound 6 in part D of compound 7: Mass Spectrum (MH[0230] +)=469.3
    • EXAMPLE 4 4-(3-{4-[(2,6-dimethylphenylcarbamoyl)-methyl]-piperazin-1-yl}-2-hydroxy-propoxy)-1H-indole-2-carboxylic acid amide (46)
  • [0231]
    Figure US20040192702A1-20040930-C00042
  • Compound 19 was prepared in the manner of compound 7 substituting the commercially available 4-glycidyloxy-2-indolecarboxamide for compound 6 in part D of compound 7: [0232]
  • Mass Spectrum (MH[0233] +)=480.4.
    • EXAMPLE 5 2-{4-[3-(benzothiazol-6-yloxy)2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethyl-phenyl)-acetamide (47)
  • [0234]
    Figure US20040192702A1-20040930-C00043
  • Synthesis of benzothiazol-6-ol (16) [0235]
    Figure US20040192702A1-20040930-C00044
  • To a solution of 6-aminobenzothiazole (1.0 g, 6.66 mmol) in water (22 mL) and H[0236] 2SO4 (16 mL) at 5° C. was added a solution of sodium nitrite (460 mg, 6.72 mmol) in water (13 mL) keeping the temperature below 5° C. The resulting solution was allowed to stir for 15 minutes. The reaction mixture was heated to 160° C. and a solution of H2SO4 (50 mL) and water (38 mL) was slowly added. The resulting mixture was allowed to stir for 1 h. The mixture was allowed to cool and an aqueous solution of 50% sodium hydroxide was added until the pH=7. The mixture was extracted with ethyl acetate and washed with brine. The combined organic was dried over MgSO4 and evaporated to yield a semi-solid. The semi-solid was purified by column chromatography (40% ethyl acetate/hexanes) to yield benzothiazo-6-ol 16 as an off-white solid.
  • Synthesis of 6-(oxiran-2-ylmethoxy)benzothiazole (48) [0237]
    Figure US20040192702A1-20040930-C00045
  • Compound 48 was prepared in the manner of compound 6 substituting compound 16 for compound 8 in partC-5 of Example 1. [0238]
  • Compound 47 was prepared in the manner of compound 7 substituting compound 48 for compound 6 in part D of compound 7: Mass Spectrum (MH[0239] +)=455.3.
    • EXAMPLE 6 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-6-yloxy)-propyl]-piperazin-1-yl}aceamide (49)
  • [0240]
    Figure US20040192702A1-20040930-C00046
  • Synthesis of 2-methylbenzothiazol-6-ol (50) [0241]
    Figure US20040192702A1-20040930-C00047
  • Compound 50 was prepared from the commercially available 6-methoxy-2-methyl-benzothiazole as described in partC-4 of Example 1. [0242]
  • Synthesis of 2-methyl-6-(oxiran-2-ylmethoxy)benzothiazole (51) [0243]
    Figure US20040192702A1-20040930-C00048
  • Compound 51 was prepared in the manner of compound 6 substituting compound 50 for compound 8 in part C-5 of Example 1. [0244]
  • Compound 49 was prepared in the manner of compound 7 substituting compound 51 for compound 6 in part D of Compound 7: Mass Spectrum (MH[0245] +)=469.3.
    • EXAMPLE 7 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-3,5-cis dimethyl-piperazine-1-yl}acetamide (52)
  • [0246]
    Figure US20040192702A1-20040930-C00049
  • Synthesis of N-(2,6-dimethylphenyl)-2-C3,5-cis dimethylpiperazin-1-yl)acetamide (53) [0247]
    Figure US20040192702A1-20040930-C00050
  • Compound 53 was prepared in the manner of compound 3 substituting 2,6-dimethylpiperazine for piperazine in part A of Example 1. [0248]
  • Compound 52 was prepared in the manner of compound 7 substituting compound 33 for compound 6 and compound 53 for compound 5 in part D of compound 7: Mass Spectrum (MH[0249] +)=497.4.
    • EXAMPLE 8 2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-(4-hydroxy-phenyl)acetamide (54)
  • [0250]
    Figure US20040192702A1-20040930-C00051
  • Synthesis of 4-aminophenyl acetate (55) [0251]
    Figure US20040192702A1-20040930-C00052
  • Compound 55 was prepared in the manner of compound 12 substituting 4-nitrophenyl acetate for compound 11 in part C-1 of Example 1. [0252]
  • Synthesis of 4-(2-chloroacetylamino)phenyl acetate (56) [0253]
    Figure US20040192702A1-20040930-C00053
  • Compound 56 was prepared in the manner of compound 3 substituting compound 55 for compound 1 in part A of Example 1. [0254]
  • Synthesis of 4-(2-piperazinylacetylamino)phenyl acetate(57) [0255]
    Figure US20040192702A1-20040930-C00054
  • Compound 57 was prepared as described in part B of Example 1 substituting compound 56 for compound 3. [0256]
  • Compound 54 was prepared in the manner of compound 7 substituting compound 33 for compound 6 and compound 57 for compound 5 in part D of compound 7: Mass Spectrum (MH[0257] +)=457.5.
    • EXAMPLE 9 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (58)
  • [0258]
    Figure US20040192702A1-20040930-C00055
  • Synthesis of phenyl-N-[3-(phenylmethoxy)phenyl]carboxamide (25) [0259]
    Figure US20040192702A1-20040930-C00056
  • To a solution of 3-benzyloxyaniline 23 (1.0 g, 5.0 mmol) and TEA (0.74 mL, 5.3 mmol) in CH[0260] 2Cl2 was added benzoyl chloride (0.61 mL, 5.26 mmol) dropwise and the mixture was allowed to stir overnight. The reaction mixture was diluted with water and the resulting solid was collected by vacuum filtration. The solid was allowed to air dry, to yield compound 25 as a white solid.
  • Synthesis of phenyl{[(3-phenylmethoxy)phenyl]amino}methane-1-thione (26) [0261]
    Figure US20040192702A1-20040930-C00057
  • A solution of compound 25 (455 mg, 1.5 mmol) and Lawesson's reagent (0.6 mol equiv) in chlorobenzene (15 mL) was heated to 120° C. and allowed to stir for 1.5 h. The reaction was allowed to cool and the solvent was evaporated (in vacuo). The residue was purified by column chromatography (ethyl acetate/hexane 1:9) to yield compound 26 as a yellow solid. [0262]
  • Synthesis of 2-phenyl-5-(phenylmethoxy)benzothiazole (27) [0263]
    Figure US20040192702A1-20040930-C00058
  • To a solution of compound 26 (960 mg, 3 mmol) in ethanol (5 mL) was added an aqueous sodium hydroxide solution (30%, 8 mol equiv). The mixture was diluted with water (6 mL) to give a final solution of 10% aqueous sodium hydroxide. The resulting solution was added to a stirred solution of potassium ferricyanide (4 mol equiv) in water at 90° C. in aliquots (1 mL) and the resulting mixture was heated for 30 min. The reaction mixture was allowed to cool and the product was extracted with ethyl acetate. The organic layer was dried and evaporated. The residue, a mixture of 27 and 28, was column purified (ethyl acetate/hexane-1:99) to provide compound 27 as a white solid. [0264]
  • Synthesis of 2-phenylbenzothiazol-5-ol (29) [0265]
    Figure US20040192702A1-20040930-C00059
  • Palladium hydroxide (100 mg) was added to a solution of 27 (260 mg, 0.8 mmol) of ethanol/cyclohexene (5 mL/2 mL) followed by warming for reflux for 16 h. The reaction mixture was cooled and the catalyst was removed by filtration (through Celite). The solvent was evaporated to provide compound 29 as a white solid. [0266]
  • Synthesis of 5-(oxiran-2-ylmethoxy)-2-phenylbenzothiazole (59) [0267]
    Figure US20040192702A1-20040930-C00060
  • Compound 59 was prepared in the manner of compound 6 substituting compound 29 for compound 8 in partC-5 of Example 1. [0268]
  • Compound 58 was prepared in the manner of compound 7 substituting compound 59 for compound 6 in part D of compound 7: Mass Spectrum (MH[0269] +)=531.6
    • EXAMPLE 10 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzoxazol-5-yloxy)-propyl)-piperazin-1-yl}acetamide (60)
  • [0270]
    Figure US20040192702A1-20040930-C00061
  • Synthesis of 5-(oxiran-2-ylmethoxy)-2-phenylbenzoxazole (61) [0271]
    Figure US20040192702A1-20040930-C00062
  • Compound 61 was prepared in the manner of compound 6 substituting ethyl benzimidate hydrochloride for compound 13 in partC1-5 of Example 1. [0272]
  • Compound 60 was prepared in the manner of compound 7 substituting compound 61 for compound 6 in part D of compound 7: Mass Spectrum (MH[0273] +)=515.3.
    • EXAMPLE 11 N-(2,6-dimethylphenyl)2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-7-yloxy)-propyl]-piperazin-1-ylacetamide (62)
  • [0274]
    Figure US20040192702A1-20040930-C00063
  • Synthesis of 7-(oxiran-2-ylmethoxy)-2-phenylbenzothiazole (63) [0275]
    Figure US20040192702A1-20040930-C00064
  • Compound 63 was prepared in the manner of compound 59 substituting deprotected compound 28 for compound 29 in example 9. [0276]
  • Compound 62 was prepared in the manner of compound 7 substituting compound 63 for compound 6 in part D of compound 7: Mass Spectrum (MH[0277] +)=531.3.
    • EXAMPLE 12 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-2-oxo-piperazin-1-yl}acetamide (64)
  • [0278]
    Figure US20040192702A1-20040930-C00065
  • Synthesis of phenylmethyl 4-{[N-(2,6-dimethylphenyl)carbamoyllmethyl}-3-oxopiperazinecarboxylate (31) [0279]
    Figure US20040192702A1-20040930-C00066
  • To a solution of compound 30 (252 mg, 1.3 mmol) in THF (13 mL) and NaH (62 mg, 1.6 mmol) was added Compound 3 (300 mg, 1.3 mmol). The solution was allowed to stir under nitrogen overnight. The reaction was quenched with water (0.1 mL) and dried over Na[0280] 2SO4 The solution was concentrated and purified using column chromatography conditions to yield compound 31 as a solid.
  • Synthesis of N-(2,6-dimethylphenyl)-2-(2-oxopiperazinyl)-acetamide (32) [0281]
    Figure US20040192702A1-20040930-C00067
  • To a solution of compound 31 in methanol (10 mL) 10% palladium on carbon was added. The reaction vessel was charged with hydrogen (40 p.s.i) and agitated for 4 h. The catalyst was removed by filtration and the filtrate was concentrated and purified using column chromatography (1:15 MeOH:DCM) to yield compound 32 as a semi solid. [0282]
  • Compound 64 was prepared in the manner of compound 7 substituting compound 33 for compound 6 and compound 32 for compound 5 in part D of compound 7: Mass Spectrum (MH[0283] +)=483.3
    • EXAMPLE 13 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (65)
  • [0284]
    Figure US20040192702A1-20040930-C00068
  • Synthesis of 5-methyoxy-2-methyl-benzoxazole (19) [0285]
    Figure US20040192702A1-20040930-C00069
  • A solution of 2-amino-4-methoxyphenol 17 (8 g, 57.4 mmol) in trimethyl orthoacetate 18 (50 mL) was heated to reflux and allowed to stir for 24 h. The reaction was allowed to cool and the excess 18 was evaporated (in vacuo). The residue was dissolved in the ethyl acetate and washed with water. The organic layer was dried over MgSO[0286] 4 and treated with activated carbon Norit A. The resulting solution was filtered through Celite 521 and evaporated to yield an oil. The oil was chromatographed on silica gel (20% ethyl acetate/hexanes) to yield compound 19 as a light yellow solid.
  • Synthesis of 2-methyl-5-oxiran-2-ylmethoxybenzoxazole (67) [0287]
    Figure US20040192702A1-20040930-C00070
  • Compound 67 was prepared in the manner of compound 6 substituting 6-hydroxy-2-methyl-benzoxazole 66 for compound 8 in part C-5 of Example 1. [0288]
  • Compound 66 in turn was obtained by the deprotection of compound 19 as described in partC-4 of Example 1. [0289]
  • Compound 65 was prepared in the manner of compound 7 substituting compound 67 for compound 6 in part D of compound 7: Mass Spectrum (MH[0290] +)=543.4
    • EXAMPLE 14 N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(4-trifluoromethyl-phenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide (68):
  • [0291]
    Figure US20040192702A1-20040930-C00071
  • Synthesis of 5-(oxiran-2-ylmethoxy)-2-(4-trifluoromethyl-phenyl)benzoxazole (69): [0292]
    Figure US20040192702A1-20040930-C00072
  • Compound 69 was prepared in the manner of compound 6 substituting 4-trifluoromethylbenzimidic acid ethyl ester hydrochloride for compound 13 in partC1-5 of Example 1. [0293]
  • Compound 68 was prepared in the manner of compound 7 substituting compound 69 for compound 6 in part D of compound 7: Mass Spectrum (MH[0294] +)=583.4
    • EXAMPLE 15 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinoxalin-2-yloxy)-propyl]-piperazin-1-yl}acetamide (70)
  • [0295]
    Figure US20040192702A1-20040930-C00073
  • Synthesis of 2-(oxiran-2-ylmethoxy)quinoxaline (71) [0296]
    Figure US20040192702A1-20040930-C00074
  • Compound 71 was prepared in the manner of compound 6 substituting quinoxaline-2-ol for compound 8 in part C-5 of Example 1. [0297]
  • Compound 70 was prepared in the manner of compound 7 substituting compound 71 for compound 6 in part D of compound 7: Mass Spectrum (MH[0298] +)=450.9.
    • EXAMPLE 16 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(pyridin-3-yloxy)-propyl]-piperazin-1-yl}acetamide (72)
  • [0299]
    Figure US20040192702A1-20040930-C00075
  • Synthesis of 3-(oxiran-2-ylmethoxy)pyridine (73) [0300]
    Figure US20040192702A1-20040930-C00076
  • Compound 73 was prepared in the manner of compound 6 substituting 3-hydroxy-pyridine for compound 8 in part C-5 of Example 1. [0301]
  • Compound 72 was prepared in the manner of compound 7 substituting compound 73 for compound 6 in part D of compound 7: Mass Spectrum (MH[0302] +)=399.4.
    • EXAMPLE 17 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-4-yloxy)-propyl]-piperazin-1-yl}acetamide (74)
  • [0303]
    Figure US20040192702A1-20040930-C00077
  • Synthesis of 4-(oxiran-2-ylmethoxy)quinoline (75) [0304]
    Figure US20040192702A1-20040930-C00078
  • Compound 75 was prepared in the manner of compound 6 substituting 4-hydroxy-quinoline for compound 8 in part C-5 of Example 1. [0305]
  • Compound 74 was prepared in the manner of compound 7 substituting compound 75 for compound 6 in part D of compound 7: Mass Spectrum (MH[0306] +)=449.4.
    • EXAMPLE 18 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl}acetamide (76)
  • [0307]
    Figure US20040192702A1-20040930-C00079
  • Synthesis of 5-(oxiran-2-ylmethoxy)isoquinoline (77) [0308]
  • Compound 77 was prepared in the manner of compound 6 substituting 5-hydroxy-isoquinoline [0309]
    Figure US20040192702A1-20040930-C00080
  • for compound 8 in part C-5 of Example 1. [0310]
  • Compound 76 was prepared in the manner of compound 7 substituting compound 77 for compound 6 in part D of compound 7: Mass Spectrum (MH[0311] +)=449.4.
    • EXAMPLE 19 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propyl]-piperazin-1-yl}acetamide (78)
  • [0312]
    Figure US20040192702A1-20040930-C00081
  • Synthesis of 6-(oxiran-2-ylmethoxy)quinoline (79) [0313]
    Figure US20040192702A1-20040930-C00082
  • Compound 79 was prepared in the manner of compound 6 substituting 6-hydroxy-quinoline for compound 8 in part C-5 of Example 1. [0314]
  • Compound 78 was prepared in the manner of compound 7 substituting compound 79 for compound 6 in part D of compound 7: Mass Spectrum (MH[0315] +)=449.4
    • EXAMPLE 20 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-quinolin-7-yloxy)-propyl]-piperazin-1-yl}acetamide (80)
  • [0316]
    Figure US20040192702A1-20040930-C00083
  • Synthesis of 2-methyl-7-(oxiran-2-ylmethoxy)quinoline (81) [0317]
    Figure US20040192702A1-20040930-C00084
  • Compound 81 was prepared in the manner of compound 6 substituting 7-hydroxy-2-methyl-quinoline for compound 8 in part C-5 of Example 1. [0318]
  • Compound 80 was prepared in the manner of compound 7 substituting compound 81 for compound 6 in part D of compound 7: Mass Spectrum (MH[0319] +)=463.5.
    • EXAMPLE 21 2-{4-[3-(benzothiazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide (39)
  • [0320]
    Figure US20040192702A1-20040930-C00085
  • Synthesis of (phenylmethoxy)-N-prop-2-enylcarboxamide (42) [0321]
    Figure US20040192702A1-20040930-C00086
  • To a solution of allylamine (3.34 g, 5.85 mmol) in dichloromethane (100 mL) and triethylamine (16 mL) benzyl chloroformate (8.25 mL, 5.78 mmol) was added at 0° C. The mixture was stirred at 0° C. for 2 hours and additional 90 minutes at RT. The solvent was removed by evaporation and the residue was purified by flash column chromatography (30% EtOAc/Hexanes) to yield compound 42 as a clear oil. [0322]
  • Synthesis of N-(oxiran-2-ylmethoxy)(phenylmethoxy)carboxamide (35) [0323]
    Figure US20040192702A1-20040930-C00087
  • Compound 42 (5.0 g, 2.61 mmol) was treated with m-chloroperbenzoic acid (11.71 g, 9.1 mmol) in dichloromethane (110 mL) at room temperature for 18 h. Dichloromethane was evaporated to afford a viscous oil which was then purified by flash column chromatography (30% EtOAc/Hexanes) to give compound 35 as a clear oil. [0324]
  • Synthesis of N-(2,6-dimethylphenyl)-2-(4-hydroxy-3-[phenylmethoxy]carbonylamino]propyl}piperazinyl)acetamide (36) [0325]
    Figure US20040192702A1-20040930-C00088
  • A solution of compound 42 (2.5 g, 1.2 mmol) and compound 5 (5.94 g, 2.4 mmol) in ethanol (100 mL) and triethylamine (3.34 mL) was refluxed for 18 h. Solvents were removed and the residue was purified by flash column chromatography (ethyl acetate) to afford compound 36 as a white solid. [0326]
  • Synthesis of 2-[4-(3-amino-2-hydroxypropyl)piperazinyl]-N-(2,6-dimethylphenyl)-acetamide (37) [0327]
    Figure US20040192702A1-20040930-C00089
  • A solution of compound 36 (3.0 g, 0.66 mmol) in methanol (70 mL) in presence of 10% Palladium on Carbon (0.337 g) was stirred under hydrogen atmosphere for 16 h. Filtration of catalyst followed by concentration afforded compound 37 as a sticky solid. [0328]
  • To a solution of compound 37 (75 mg) in ethanol (2 mL) was added triethylamine (0.13 mL) and 2-chlorobenzthiazole (87 mg) followed by warming to reflux for 16 h. The reaction mixture was concentrated and purified by preparative TLC (5% MeOH/Dichloromethane) to give Compound 39 as a white solid. Mass Spectrum (MH[0329] +)=454.4.
    • EXAMPLE 22 2-{4-[3-(benzoxazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide (82)
  • [0330]
    Figure US20040192702A1-20040930-C00090
  • Compound 82 was prepared in the manner of compound 39 by substituting 2-chloro-benzoxazole for 2-chloro-benzothiazole as in example 21. Mass Spectrum (MH[0331] +)=438.4.
    • EXAMPLE 23
  • Mitochondrial Assays [0332]
  • Rat heart mitochondria were isolated by the method of Nedergard and Cannon (Methods in Enzymol. 55, 3, 1979). [0333]
  • Palmitoyl CoA oxidation—The Palmityl CoA oxidation was carried out in a total volume of 100 micro liters containing the following agents: 110 mM KCl, 33 mM Tris buffer at pH 8, 2 mM KPi, 2 mM MgCl[0334] 2, 0.1 mM EDTA, 14.7 microM defatted BSA, 0.5 mM malic acid, 13 mM camitine, 1 mM ADP, 52 micrograms of mitochondrial protein, and 16 microM 1-C14 palmitoyl CoA (Sp. Activity 60 mCi/mmole; 20 microCi/ml, using 5 microliters per assay). The compounds of this invention were added in a DMSO solution at the following concentrations: 100 microM, and 50 microM. In each assay, a DMSO control was used. After 15 min at 30° C., the enzymatic reaction was centrifuged 20,000 g for 1 min), and 70 microliters of the supernatant was added to an activated reverse phase silicic acid column (approximately 0.5 ml of silicic acid). The column was eluted with 2 ml of water, and 0.5 ml of the eluent was used for scintillation counting to determine the amount of C14 trapped as C14 bicarbonate ion.
  • The results are shown in Table 1 and Table 1a below. [0335]
    TABLE 1
    Inhibition of mitochondrial fatty acid oxidation using palmitoyl
    CoA as substrate - % of Control at 2 concentrations and IC50.
    Compound # 100 μm (%) 50 μm (%) IC50 (μm)
     7 — 77 —
    39 27 — —
    43 21 — —
    45 87 —  ˜20
    46 61 — ˜125
    47 70 — ˜125
    49  3 — —
    52 95 —  ˜1
    54 81 —  ˜8
    60 — 61 —
    62 — 62 —
    64 41 — —
    68 — 68 —
    70 12 — —
    72  8 — —
    74 12 — —
    76 26 — —
    78 42 — —
    80 22 — —
    82 22 — —
  • [0336]
    TABLE IA
    Effect of Compounds of the Invention on Palmitoyl CoA Oxidation (IC50).
    Name IC50 uM
    N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methylbenzothi-azol-5- 0.7
    yloxy)propyl]-3,5-dimethylpiperazinyl}acetamide
    2-{(3R)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]- 2
    3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide
    2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl](3S)- 5
    3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide
    2-{(3R)-4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]- 10
    3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide
    2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]- 0.2
    3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,5- 2.5
    dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,5- 0.07
    dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide
    N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5- 15
    yloxy)propyl]piperazinyl}acetamide
    2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N- 4
    (2,6-dimethylphenyl)acetamide
    2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,3- 0.45
    dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}- 8
    N-(2,6-dimethylphenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}- 0.18
    N-(3-phenylphenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol--yloxy)propyl]piperazinyl}- 0.33
    N-(4-phenoxyphenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}- 0.39
    N-(3-phenoxyphenyl)acetamide
    2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3- 0.41
    methylpiperazinyl}-N-(4-cyanophenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}- 0.46
    N-(4-phenylphenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N- 1.7
    (4-methylphenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}- 2
    N-[4-(4-chlorophenoxy)phenyl]acetamide
    2-{4-[(2S)-3-(2-cyclohexylbenzothiazol-5-yloxy)-2-hydroxypropyl]piperazinyl}- 6.5
    N-(2,6-dimethylphenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}- 7.6
    N-[4-(trifluoromethyl)phenyl]acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}- 11.3
    N-(4-phenoxyphenyl)acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-
    N-[4-(trifluoromethyl)phenyl]acetamide
    2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl} 12
    piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide
    2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl} 12.9
    piperazinyl)-N-[4-(trifluoromethyl)phenyl]acetamide
    2-[4-((2S)-2-hydroxy-3-{2-[3-(trifluoromethyl)phenyl]benzoxazol-5- 13
    yloxy}propyl)piperazinyl]-N-(2,6-dimethylphenyl)acetamide
    2-((3S)-4-{(2S)-3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}- 16
    3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide
    2-((3S)-4-{(2S)-3-[2-(2-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}- 19
    3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide
    2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl} 20
    piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide
    2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}- 26
    N-(3-phenylphenyl)acetamide
    • EXAMPLE 25
  • Metabolic Stability: As a measure of metabolic stability the compounds of this invention were incubated with human liver S-9 microsomal fractions. After, 30 minutes at 37 C, the amount of parent drug remaining was determined using LC-mass spec. The response factors for each compound was determined by establishing a standard curve and using an internal standard during the analysis of the samples. An average of five experiments for percentage of ranolazine remaining at the 30 minute time point is 57%. The compounds of this invention were assayed as described in the protocol below and the percentage of parent remaining was divided by the average % of ranolazine remaining (57%) affording a metabolic stability factor. A compound with a stability number greater than 1.2 has a better stability than ranolazine in the liver S-9 assay. A compound with a stability number between 1.2 and 0.8 has an equivalent stability in the liver S-9 assay. A compound with a stability number less than 0.8 is less stable than ranolazine in the liver S-9 assay. [0337]
  • The purpose of this experiment is to compare the percentages remaining for compounds of this invention with the percentage remaining for ranolazine after 30 minutes of incubation with human liver S9 fractions. [0338]
    • Reagents
  • The following reagents were used; Potassium phosphate, 0.5M pH 7.4 (incubation buffer), kept at room temperature; 0.05M MgCl[0339] 2 kept at 4° C.; β-Nicotinamide adenine dinucleotide phosphate, tetrasodium salt, reduced form (NADPH), 0.02M solution in water (˜16.6 mg/mL) from Sigma Lot # 79H7044 prepared on day of use. 1 mM of ranolazine or Compounds 43, 45, 47, 52, 70, 74, 76, 78, and 80 in ACN further diluted to obtain 100 μM in 10% ACN; Human S9 stock: 20 mg/mL from Gentest.
    • Procedure
  • Incubation mixtures were prepared as follows: [0340]
    TABLE 2
    Volume per 0.25 mL
    of Incubation Final
    Component Mixture concentration
    10 μM CVT 25 μL   10 μM
    compounds
    MgCl2 25 μL 0.005 M
    NADPH 25 μL 0.002 M
    S9 25 μL    2 mg/mL
    Incubation Buffer 25 μL  0.05 M
    Water 125 μL  —
  • Combine all components with incubation buffer and re-pipette 200 μL/tube+25 μL of the compound being tested along with 25 μL of S-9. [0341]
  • After 5 min of pre-incubation at 37° C., at 0 and 30 min after starting the reaction, a 50 μl aliquot of the incubation mixture was removed and added to 100 μL of 9:1 acetonitrile: methanol containing the internal standard. [0342]
  • The mixture was centrifuged and a 100 μL aliquot of the supernatant was diluted in 1 mL of solvent C (0.1% Formic Acid in water). Then samples were analyzed for change between the ratio of compound to internal standard at time zero and 30 minutes by LC/MS (injected 10 μL). [0343]
    • Analytical and Data Calculations
  • Samples were analyzed for the starting compounds and potential metabolite/s by LC/MS using an internal standard and an ODS-C18 column with a flow rate of 0.25 ml/min. Following the above procedure resulted in the following relative stability factors as compared to ranolazine for the compounds of this invention as illustrated in Table 3. [0344]
    TABLE 3
    Compound # Liver S9 Stability Factor
    43 0.6
    45 0.8
    46 1.1
    47 1.5
    52 0.5
    70 0.1
    74 1.0
    76 0.8
    78 0.6
    80 0.5
    • EXAMPLE 26
  • A. Synthesis of tert-butyl (3S)-3-methylpiperazinecarboxylate, a Compound of Formula (B) [0345]
    Figure US20040192702A1-20040930-C00091
  • 1-(tert-butoxycarbonyl)-2-tert-butyl-3-methyl-4-imidazolidinone (2 g, 8.3 mmol) (BOC-ON), in chloroform (15 ml), was added to (2S)-2-methylpiperazine (5 g, 50 mmol), a compound of formula (A), in a mixture of triethylamine (1.25 g, 12.5 mmol) and chloroform. The mixture was stirred for about 15 hours and then washed with water, the solvent removed in vacuo. The residue was purified by column chromatography, to give tert-butyl (3S)-3-methylpiperazinecarboxylate, a compound of formula (B). [0346]
    • EXAMPLE 27
  • B. Synthesis of tert-butyl (3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-6-yloxy)propyl]-3-methylpiperazinecarboxylate a Compound of Formula (D). [0347]
    Figure US20040192702A1-20040930-C00092
  • The compound of formula (B) was reacted with 2-methyl-6-(oxiran-2-ylmethoxy)benzothiazole (3 g, 7.3 mmol), a compound of formula (C), in ethanol. The reaction was refluxed for about 24 hours. When the reaction was substantially complete, the solvent was removed under reduced pressure, followed by preparative thin layer chromatography to render tert-butyl (3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-6-yloxy)propyl]-3-methylpiperazinecarboxylate, a compound of formula (D). [0348]
    • EXAMPLE 28
  • C. Preparation of a Compound of (2S)-1-((2S)-2-methylpiperazinyl)-3-(2-methylbenzothiazol-6-yloxy)propan-2-ol, a Compound of Formula (E). [0349]
    Figure US20040192702A1-20040930-C00093
  • tert-Butyl (3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-6-yloxy)propyl]-3-methylpiperazinecarboxylate (3 g) in trifluoroacetic acid (50 ml) was stirred at room temperature for 72 hours. The TFA was removed by evaporation under reduced pressure and the residue was dissolved in 50 ml of MEOH. The pH adjusted to between pH8-pH9 using tris-resin(Argonaut) rendering (2S)-1-((2S)-2-methylpiperazinyl)-3-(2-methylbenzothiazol-6-yloxy)propan-2-ol, which was used without further purification. [0350]
    • EXAMPLE 29
  • D. Preparation of a Compound of Formula (I). [0351]
    Figure US20040192702A1-20040930-C00094
  • (2S)-1-((2S)-2-methylpiperazinyl)-3-(2-methylbenzothiazol-6-yloxy)propan-2-ol, a compound of formula (E), and N-(2,6-dimethylphenyl)-2-chloroacetamide, a compound of formula (F), were dissolved in dichloroethane. A polystyrene styrene diisopropylethylamine (PS-DIEA) resin was added and the vial shaken at 80° C. overnight. After cooling to room temperature, 200 mg each of Polystrene-Isocyanate resin were added and shaken at about room temperature overnight. After cooling to room temperature, contents of the vial were transferred into a flit fitted syringe, filtered, resins washed with dichloroethane repeatedly. After concentration by Speedvac™, the crude mixture was purified with semi-preparative HPLC (ACN/water, 0.1% TFA), fractions were analyzed by MS and HPLC to give 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, a compound of Formula (I), which was isolated as a free base. [0352]
  • Similarly by optionally replacing (2S)-1-((2S)-2-methylpiperazinyl)-3-(2-methylbenzothiazol-6-yloxy)propan-2-ol, with other compounds of formula (E) and optionally replacing N-(2,6-dimethylphenyl)-2-chloropropanamide, with other compounds of formula (F) the following compounds were made: [0353]
  • N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,5-dimethylpiperazinyl}acetamide; [0354]
  • 2-{(3R)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0355]
  • 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl](3S)-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0356]
  • 2-{(3R)-4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methyl-piperazinyl}-N-(2,6-dimethylphenyl)acetanmide; [0357]
  • 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methyl-piperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0358]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,5-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0359]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,5-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0360]
  • N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}acetamide; [0361]
  • 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0362]
  • 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,3-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0363]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0364]
  • 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methyl-piperazinyl}-N-(4-methylphenyl)acetamide; [0365]
  • 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methyl-piperazinyl}-N-[4-(trifluoromethyl)phenyl]acetamide; [0366]
  • N-((1S)-1-(2-naphthyl)ethyl)-2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}acetamide; [0367]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3-phenylphenyl)acetamide; [0368]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazolyloxy)propyl]piperazinyl}-N-(4-phenoxyphenyl)acetamide; [0369]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3-phenoxyphenyl)acetamide; [0370]
  • 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(4-cyanophenyl)acetamide; [0371]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-phenylphenyl)acetamide; [0372]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-methylphenyl)acetamide; [0373]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-chlorophenoxy)phenyl]acetamide; [0374]
  • 2-{4-[(2S)-3-(2-cyclohexylbenzothiazol-5-yloxy)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0375]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-(trifluoromethyl)phenyl]acetamide; [0376]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(4-phenoxyphenyl)acetamide; [0377]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-(trifluoromethyl)phenyl]acetamide; [0378]
  • 2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0379]
  • 2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[4-(trifluoromethyl)phenyl]acetamide; [0380]
  • 2-[4-((2S)-2-hydroxy-3-{2-[3-(trifluoromethyl)phenyl]benzoxazol-5-yloxy}propyl)-piperazinyl]-N-(2,6-dimethylphenyl)acetamide; [0381]
  • 2-((3S)-4-{(2S)-3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide; [0382]
  • 2-((3S)-4-{(2S)-3-[2-(2-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide; [0383]
  • 2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0384]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(3-phenylphenyl)acetamide; [0385]
  • 2-{4-[([0386] 2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide;
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(2-phenylphenyl)acetamide; [0387]
  • 2-((3S)-4-{(2S)-3-[2-(2-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide; [0388]
  • 2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0389]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(3-phenylphenyl)acetamide; [0390]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0391]
  • 2-{4-[([0392] 2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(2-phenylphenyl)acetamide;
  • 2-(4-{(2S)-3-[2-(2-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-(2,6-dimethylphenyl)acetamide; [0393]
  • 2-[4-((2S)-2-hydroxy-3-{2-[2-(trifluoromethyl)phenyl]benzoxazol-5-yloxy}propyl)-piperazinyl]-N-(2,6-dimethylphenyl)acetamide; [0394]
  • 2-{4-[(2S)-2-hydroxy-3-(2-propylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide; [0395]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0396]
  • 2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0397]
  • 2-{4-[([0398] 2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperzinyl}-N-(3-phenoxyphenyl)acetamide;
  • 2-{4-[([0399] 2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(2-phenoxyphenyl)acetamide;
  • 2-{4-[([0400] 2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2-phenylphenyl)acetamide;
  • 2-{4-[([0401] 2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-cyanophenyl)acetamide;
  • 2-(4-{(2S)-2-hydroxy-3-[2-(2-methyl(1,3-thiazol-4-yl))ethoxy]propyl}piperazinyl)-N-(2,6-dimethylphenyl)acetamide; [0402]
  • 2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(4-phenylphenyl)acetamide; and [0403]
  • 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3-phenoxyphenyl)acetamide. [0404]
    • EXAMPLE 30 Preparation of a Compound of Formula (C)
  • A. Preparation of a Compound of Formula (C), in which q is Oxygen and m is 1. [0405]
    Figure US20040192702A1-20040930-C00095
  • A mixture of 2-methylbenzothiazol-5-ol, a compound of formula (a) (6.0 g, 36 mmol), (S)-(+)-epichlorohydrin, a compound of formula (b) (20 ml, 182 mmol), and potassium carbonate (20 g, 144 mmol) in acetone (100 ml), was heated to reflux and allowed to stir overnight. The solution was allowed to cool and filtered through Celite 512. The filtrate was evaporated under reduced pressure to yield an oil. The oil was chromatographed on silica gel, eluting with 20% ethyl acetate/hexanes, to yield 2-methyl-5-(S)-(oxiran-2-ylmethoxy)benzothiazole as white solid (6.2 g, 28 mmol). [0406]
  • B. Preparation of a Compound of Formula (C) in which q is Oxygen, and m is 1. [0407]
  • Similarly, following the procedure of 1A above, but replacing 2-methylbenzothiazol-5-ol with 2-phenylbenzoxazol-5-ol, a compound of formula (C) where R[0408] 17 is 2-phenylbenzoxazol-5-yl, q is oxygen, and m is 1 was prepared, namely 2-phenyl-5-(oxiran-2-ylmethoxy)benzoxazole.
  • Similarly, the following compounds of formula (C) were prepared: [0409]
  • 2-cyclohexyl-5-(oxiran-2-ylmethoxy)benzoxazole; [0410]
  • 5-(oxiran-2-ylmethoxy)-2-phenylbenzoxazole; [0411]
  • 2-(4-chlorophenyl)-5-(oxiran-2-ylmethoxy)benzoxazole; [0412]
  • 5-(oxiran-2-ylmethoxy)-2-[3-(trifluoromethyl)phenyl]benzoxazole; [0413]
  • 2-(3-fluorophenyl)-5-(oxiran-2-ylmethoxy)benzoxazole; [0414]
  • 2-(2-chlorophenyl)-5-(oxiran-2-ylmethoxy)benzoxazole; [0415]
  • 5-(oxiran-2-ylmethoxy)-2-[2-(trifluoromethyl)phenyl]benzoxazole; [0416]
  • 5-(oxiran-2-ylmethoxy)-2-propylbenzthiazole; and [0417]
  • 2-(2,4-dichlorophenyl)-5-(oxiran-2-ylmethoxy)benzothiazole. [0418]
    • EXAMPLE 31 Synthesis of 2-amino-4-methoxyphenol a Compound of Formula (d)
  • [0419]
    Figure US20040192702A1-20040930-C00096
  • Commercially available 4-methoxy-2-nitrophenol (1 g, 5.9 mmol), a compound of formula (C) was dissolved in 10 mL of methanol, and then 10% Pd/C was added to the mixture. The mixture was hydrogenated in a Parr™ shaker at 30 psi until consumption of hydrogen stopped. The mixture was filtered through Celite and concentrated, to yield 2-amino-4-methoxyphenol a compound of formula (d), which was used without further purification. [0420]
    • EXAMPLE 32 Synthesis of 2-(2,4-dichlorophenyl)-5-methoxybenzoxazole, a Compound of Formula (f)
  • [0421]
    Figure US20040192702A1-20040930-C00097
  • To a solution of 2-amino-4-methoxyphenol (1 g, 7.1 mmol), a compound of formula (d) in 20 mL MeOH was added 2,4-dichlorobenzaldehyde (1.2 g, 7.1 mmol), a compound of formula (e). The mixture was heated at 45° C. for 12 hours. The mixture was concentrated under reduced pressure and the residue was dissolved in 50 mL dichloromethane. To the solution was added DDQ (1.7 g, 7.8 mmol), and the mixture was allowed to stir at room temperature for 30 minutes. The reaction mixture was then diluted with an additional 30 mL of dichloromethane and washed sequentially with saturated NaHCO[0422] 3 (2×50 mL) and brine. The organic layer was separated, dried over MgSO4 and concentrated under reduced pressure to yield 2-(2,4-dichlorophenyl)-5-methoxybenzoxazole, a compound of formula (f), which was purified using flash column chromatography.
    • EXAMPLE 33 Synthesis of 2-(2,4-dichlorophenyl)benzoxazol-5-ol, a compound of formula (g)
  • [0423]
    Figure US20040192702A1-20040930-C00098
  • 2-(2,4-dichlorophenyl)-5-methoxybenzoxazole (0.5 g, 1.7 mmol) was dissolved in 25 mL of dichloromethane. To the solution was added BBr[0424] 3 (8 mmol) and the mixture was stirred at room temperature for 48 hours. The mixture was then diluted with 25 mL dichloromethane, and washed sequentially with saturated NaHCO3 (2×25 mL) and brine. The organic layer was separated, dried over MgSO4 and filtered. The solvent was removed, to provide 2-(2,4-dichlorophenyl)benzoxazol-5-ol, a compound of formula (g), which was purified using flash chromatography.
    • EXAMPLE 34 Synthesis of 2-(2,4-dichlorophenyl)-5-(oxiran-2-ylmethoxy)benzoxazole, a compound of formula (C)
  • [0425]
    Figure US20040192702A1-20040930-C00099
  • A mixture of 2-(2,4-dichlorophenyl)benzoxazol-5-ol, a compound of formula (g) (6.0 g, 36 mmol), (S)-(+)-epichlorohydrin (3.3 g, 315 mmol), a compound of formula (b) (20 ml, 182 mmol), and potassium carbonate (20 g, 144 mmol) in acetone (100 ml) was heated to reflux and stirred overnight. The solution was allowed to cool and filtered through Celite 512. The filtrate was evaporated under reduced pressure, to yield an oil. The oil was chromatographed on silica gel, eluting with 20% ethyl acetate/hexanes, to provide 2-(2,4-dichlorophenyl)-5-(oxiran-2-ylmethoxy)benzoxazole as a white solid (6.2 g, 28 mmol). [0426]
    • EXAMPLE 35 Preparation of N-(2,6-dimethylphenyl)-2-bromoacetamide, a compound of formula (F)
  • [0427]
    Figure US20040192702A1-20040930-C00100
  • To a mixture of 2,6-dimethylaniline (3 g, 21.4 mmol), a compound of formula (i) and chloroacetic anhydride (1.5 g, 14 mmol), a compound of formula (j), in tetrahydrofuran (100 mL) was added triethylamine (3 mL, 30 mmol). The mixture was allowed to stir for 1 hour at 0° C. and for an additional 1 hour at room temperature. The solvent was removed and ether (100 mL) was added to the residue, the ether layer was washed twice with 10% citric acid (50 mL), dried over MgSO[0428] 4 and filtered. The solvent was removed to afford N-(2,6-dimethylphenyl)-2-chloroacetamide, a compound of Formula (F), as a white solid.
  • Similarly by replacing 2,6-dimethylaniline with other compounds of formula (i) the following compounds of formula (F) were made: [0429]
  • 2-chloro-N-(4-methylphenyl)acetamide; [0430]
  • 3-chloro-N-(4-methylphenyl)acetamide; [0431]
  • 3-chloro-N-(2-phenylphenyl)acetamide; [0432]
  • 3-chloro-N-(3-phenylphenyl)acetamide; [0433]
  • 3-chloro-N-(4-phenylphenyl)acetamide; [0434]
  • 3-chloro-N-(2-phenoxyphenyl)acetamide; [0435]
  • 3-chloro-N-(3-phenoxyphenyl)acetamide; [0436]
  • 3-chloro-N-(4-phenoxyphenyl)acetamide; [0437]
  • 3-chloro-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide; [0438]
  • N-(2,6-dimethylphenyl)-3-chloroacetamide; and [0439]
  • 3-chloro-N-(4-methylphenyl)acetamide. [0440]

Claims (47)

We claim:
1. A substituted piperazine compound of Formula I:
Figure US20040192702A1-20040930-C00101
wherein:
m is 1, 2, or 3;
q is —NH—, oxygen, or sulfur;
R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, halo, CF3, OH, and C1-15 straight or branched alkyl;
R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen and C1-4 straight or branched alkyl, and
R17 is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of halo, C1-15 straight or branched alkyl, aryl, cycloalkyl, and CF3, wherein the aryl substituents are optionally substituted with 1 substituent selected from the group consisting of methyl, halo and CF3.
2. The compound of claim 1, wherein m is 1 and q is oxygen;
3. The compound of claim 2, wherein:
R1, R3, R5, R11, R12, R14 are hydrogen or methyl; and
R2, R4, R9, R10, R13, R15 and R16 are hydrogen.
4. The compound of claim 3, wherein R1 and R5 are methyl, R3, R11, R12, and R14 are hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}acetamide, or an enantiomer or diastereoisomer thereof.
5. The compound of claim 3, wherein the enantiomer is 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide.
6. The compound of claim 3, wherein the enantiomer is 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide.
7. The compound of claim 3, wherein R1 and R5 are methyl, R3, R11, R12, and R14 are hydrogen, and R17 is 2-cyclohexylbenzothiazol-5-yl, namely 2-{4-[3-(2-cyclohexylbenzothiazol-5-yloxy)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
8. The compound of claim 3, wherein R1 and R5 are methyl, R3, R11, R12, and R14 are hydrogen, and R17 is 2-(3-trifluoromethylphenyl)-benzoxazol-5-yl, namely (±)-2-[4-(2-hydroxy-3-{2-[3-(trifluoromethyl)phenyl]-benzoxazol-5-yloxy}propyl)piperazinyl]-N-(2,6-dimethylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
9. The compound of claim 3, wherein R1 and R5 are methyl, R3, R11, R12 and R14 are hydrogen, and R17 is 2-(2-chlorophenyl)benzoxazol-5-yl, namely (±)-2-(4-{3-[2-(2-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-(2,6-dimethylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
10. The compound of claim 3, wherein R1 and R5 are methyl, R3, R11, R12 and R14 are hydrogen, and R17 is 2-propylbenzothiazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-propylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
11. The compound of claim 3, wherein R1 and R5 are methyl, R12 and R14 represent cis dimethyl, R3 and R11 are hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methylbenzothiazole-5-yloxy)propyl]-3,5-cis dimethylpiperazinyl}acetamide, or an enantiomer or diastereoisomer thereof.
12. The compound of claim 11, wherein the diastereoisomer is N-(2,6-dimethylphenyl)-2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazole-5-yloxy)propyl]-3,5-cis dimethylpiperazinyl}acetamide.
13. The compound of claim 11, wherein the diastereoisomer is N-(2,6-dimethylphenyl)-2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazole-5-yloxy)propyl]-3,5-cis dimethylpiperazinyl}acetamide.
14. The compound of claim 3, wherein R1, R5 and R12 are methyl, R3, R11, and R14 are hydrogen, and R17 is 2-(3-fluorophenyl)benzoxazol-5-yl, namely (±)-2-(4-{3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
15. The compound of claim 14, wherein the diastereoisomer is 2-((3R)-4-{(2S){3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide.
16. The compound of claim 14, wherein the diastereoisomer is 2-((3S)-4-{(2S){3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide.
17. The compound of claim 14, wherein the diastereoisomer is 2-((3R)-4-{(2R){3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide.
18. The compound of claim 14, wherein the diastereoisomer is 2-((3S)-4-{(2R){3-[2-(3-fluorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide.
19. The compound of claim 3, wherein R1, R5 and R12 are methyl, R3, R11, and R14 are hydrogen, and R17 is 2-methylbenzothiazol-6-yl, namely (±)-2-{(3R)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-6-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
20. The compound of claim 3, wherein R1, R5 and R12 are methyl, R3, R11, and R14 are hydrogen, and R17 is 2-(2-chlorophenyl)benzoxazol-5-yl, namely (±)-2-(4-{3-[2-(2-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}-3-methylpiperazinyl)-N-(2,6-dimethylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
21. The compound of claim 3, wherein R1, R5 and R12 are methyl, R3, R11, and R14 are hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
22. The compound of claim 3, wherein R1, R5, R11 and, R12 are methyl, R3 and R14 are hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,3-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
23. The compound of claim 3, wherein R3 and R12 are methyl, R1, R5, R11, and R14 are hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]3-methylpiperazinyl}-N-(4-methylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
24. The compound of claim 2, wherein R3 is methyl, R1, R5, R11, R12 and R14 are hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-methylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
25. The compound of claim 2, wherein:
R1, R2, R3, and R4 are hydrogen, cyano, trifluoromethyl, or phenyl;
R5, R9, R10, R11, R13, R14, R15 and R16 are hydrogen; and
R12 is hydrogen or methyl.
26. The compound of claim 25, wherein R1, R2 and R4 are hydrogen, R3 is trifluoromethyl, R12 is methyl, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-[4-(trifluoromethyl)phenyl]acetamide, or an enantiomer or diastereoisomer thereof.
27. The compound of claim 25, wherein R1, R2, R4 and R12 are hydrogen, R3 is trifluoromethyl, and R17 is 2-(4-chlorophenyl)benzoxazol-5-yl, namely, (±)-2-(4-{3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[4-(trifluoromethyl)phenyl]acetamide, or an enantiomer or diastereoisomer thereof.
28. The compound of claim 25, wherein R1, R2, R4 and R12 are hydrogen, R3 is cyano, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-cyanophenyl)acetamide, or an enantiomer or diastereoisomer thereof.
29. The compound of claim 25, wherein R is phenyl, R2, R3, R4 and R12 are hydrogen, and R17 is 2-phenylbenzoxazol-5-yl, namely (±)-2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(2-phenylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
30. The compound of claim 25, wherein R2 is phenyl, R1, R3, R4 and R12 are hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-methylbenzothiazole-5-yloxy)propyl]piperazinyl}-N-(3-phenylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
31. The compound of claim 25, wherein R2 is phenyl, R1, R2, R4 and R12 are hydrogen, and R17 is 2-phenylbenzoxazol-5-yl, namely (±)-2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(3-phenylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
32. The compound of claim 25, wherein R3 is phenyl, R1, R2, R4 and R12 are hydrogen, and R17 is 2-phenylbenzoxazol-5-yl, namely (±)-2{4-[2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(4-phenylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
33. The compound of claim 25, wherein R3 is phenyl, R1, R2, R4 and R12 are hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-phenylphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
34. The compound of claim 2, wherein:
R1, R4, R5, R9, R10, R11, R12, R13, R14, R15 and R16 are hydrogen; and
R2 and R3 are hydrogen or phenoxy optionally substituted with halo.
35. The compound of claim 34, wherein R3 is phenoxy, R2 is hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-yloxy)propyl]piperazinyl}-N-(4-phenoxyphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
36. The compound of claim 34, wherein R3 is phenoxy, R2 is hydrogen, and R17 is 2-phenylbenzoxazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(4-phenoxyphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
37. The compound of claim 34, wherein R3 is 4-chlorophenoxy, R2 is hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[2-hydroxy-3-(2-methylbenzothiazole-5-yloxy)propyl]piperazinyl}-N-[4-(4-chlorophenoxy)phenyl]acetamide, or an enantiomer or diastereoisomer thereof.
38. The compound of claim 34, wherein R2 is phenoxy, R3 is hydrogen, and R17 is 2-phenylbenzoxazol-5-yl, namely (±)-2-{4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]piperazinyl}-N-(3-phenoxyphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
39. The compound of claim 34, wherein R2 is phenoxy, R3 is hydrogen, and R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3-phenoxyphenyl)acetamide, or an enantiomer or diastereoisomer thereof.
40. The compound of claim 2, wherein:
R1, R3, R4, R9, R10, R11, R12, R13, R14, R15 and R16 are hydrogen;
R2 is hydroxymethyl; and
R5 is methyl.
41. The compound of claim 40, wherein R17 is 4-chlorophenylbenzoxazol-5-yl, namely (±)-2-(4-{(2S)-3-[2-(4-chlorophenyl)benzoxazol-5-yloxy]-2-hydroxypropyl}piperazinyl)-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide, or an enantiomer or diastereoisomer thereof
42. The compound of claim 40, wherein R17 is 2-methylbenzothiazol-5-yl, namely (±)-2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[2-(hydroxymethyl)-6-methylphenyl]acetamide, or an enantiomer or diastereoisomer thereof.
43. A method of treating a disease state in a mammal that is alleviable by treatment with a partial fatty acid oxidation inhibitor, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of claim 1.
44. The method of claim 43, wherein the disease state is damage to skeletal muscles resulting from trauma or shock, or a cardiovascular disease.
45. The method of claim 43, wherein the cardiovascular disease is atrial arrhythmia, intermittent claudication, ventricular arrhythmia, Prinzmetal's (variant) angina, stable angina, exercise induced angina, congestive heart disease, or myocardial infarction.
46. The method of claim 43, wherein the disease state is diabetes.
47. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 1.
US10/813,743 2000-10-23 2004-03-31 Heteroaryl alkyl piperazine derivatives Abandoned US20040192702A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/813,743 US20040192702A1 (en) 2000-10-23 2004-03-31 Heteroaryl alkyl piperazine derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/694,155 US6573264B1 (en) 2000-10-23 2000-10-23 Heteroaryl alkyl piperazine derivatives
US10/313,818 US6849632B2 (en) 2000-10-23 2002-12-05 Heteroaryl alkyl piperazine derivatives
US10/813,743 US20040192702A1 (en) 2000-10-23 2004-03-31 Heteroaryl alkyl piperazine derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/313,818 Continuation US6849632B2 (en) 2000-10-23 2002-12-05 Heteroaryl alkyl piperazine derivatives

Publications (1)

Publication Number Publication Date
US20040192702A1 true US20040192702A1 (en) 2004-09-30

Family

ID=24787627

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/694,155 Expired - Fee Related US6573264B1 (en) 2000-10-23 2000-10-23 Heteroaryl alkyl piperazine derivatives
US10/398,636 Abandoned US20040029889A1 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
US10/313,818 Expired - Lifetime US6849632B2 (en) 2000-10-23 2002-12-05 Heteroaryl alkyl piperazine derivatives
US10/813,743 Abandoned US20040192702A1 (en) 2000-10-23 2004-03-31 Heteroaryl alkyl piperazine derivatives

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09/694,155 Expired - Fee Related US6573264B1 (en) 2000-10-23 2000-10-23 Heteroaryl alkyl piperazine derivatives
US10/398,636 Abandoned US20040029889A1 (en) 2000-10-23 2001-10-19 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
US10/313,818 Expired - Lifetime US6849632B2 (en) 2000-10-23 2002-12-05 Heteroaryl alkyl piperazine derivatives

Country Status (23)

Country Link
US (4) US6573264B1 (en)
EP (1) EP1339701B1 (en)
JP (1) JP4138489B2 (en)
KR (1) KR20030044029A (en)
CN (1) CN1303074C (en)
AR (1) AR034173A1 (en)
AT (1) ATE353882T1 (en)
AU (1) AU2002255466B2 (en)
CA (1) CA2426535A1 (en)
DE (1) DE60126643T2 (en)
ES (1) ES2279790T3 (en)
HU (1) HUP0303552A3 (en)
IL (2) IL155294A0 (en)
MX (1) MXPA03003531A (en)
NO (2) NO20031784L (en)
NZ (1) NZ525259A (en)
PL (1) PL362004A1 (en)
PT (1) PT1339701E (en)
RU (1) RU2243970C1 (en)
SI (1) SI1339701T1 (en)
TW (1) TWI286135B (en)
WO (1) WO2002064576A1 (en)
ZA (1) ZA200302990B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1865945A4 (en) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd Combination therapy for endothelial dysfunction, angina and diabetes

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US7001909B2 (en) * 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
DK1406898T3 (en) * 2001-07-19 2005-05-30 Cv Therapeutics Inc Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US7056924B2 (en) * 2002-07-18 2006-06-06 Cv Therapeutics, Inc. Substituted heterocyclic compounds
TW200504033A (en) * 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
EP1806346B1 (en) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
JP2006510670A (en) * 2002-12-05 2006-03-30 シーブイ・セラピューティクス・インコーポレイテッド Substituted heterocyclic compounds
NZ541069A (en) * 2003-01-03 2008-09-26 Cv Therapeutics Inc Piperazine derivatives as fatty acid oxidation inhibitors
ES2387909T3 (en) * 2003-01-14 2012-10-03 Cytokinetics, Inc. Compounds, compositions and procedures for treating heart failure
NZ541306A (en) * 2003-01-17 2008-07-31 Cv Therapeutics Inc Substituted piperazine and piperidine derivatives useful in the treatment of cardiovascular diseases
NZ544449A (en) * 2003-06-23 2008-10-31 Cv Therapeutics Inc Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
WO2005061470A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
US7163944B2 (en) * 2004-01-26 2007-01-16 Kowa Co., Ltd. Cyclic diamine compound and pharmaceutical containing the same
PL216049B1 (en) 2004-06-17 2014-02-28 Cytokinetics Inc Urea derivatives, compositions containing urea derivatives as well as the application of urea derivatives in the production of medications used to treat systolic heart failure
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
AU2005282492A1 (en) * 2004-09-08 2006-03-16 Gilead Palo Alto, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US20060074105A1 (en) * 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
WO2007075377A2 (en) * 2005-12-15 2007-07-05 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
JP5178526B2 (en) * 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
WO2007079003A2 (en) * 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Amide inhibitors of leukotriene a4 hydrolase
WO2010056527A2 (en) * 2008-10-30 2010-05-20 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US8759382B2 (en) 2010-09-29 2014-06-24 Teva Pharmaceutical Industries Ltd. Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use
CN107108534B (en) 2014-08-29 2023-05-09 Chdi基金会股份有限公司 Probes for imaging huntingtin
ES2919779T3 (en) 2017-06-20 2022-07-28 Imbria Pharmaceuticals Inc 1-[(2,3,4-trimethoxyphenyl)methyl]-piperazine derivative, compositions thereof and methods for increasing the efficiency of cardiac metabolism
EP4497474A3 (en) 2018-10-17 2025-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
RU2751878C2 (en) * 2018-12-06 2021-07-19 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" 1-(methoxybenzyl)-4-[2-((methoxybenzyl)amino)ethyl]piperazines, which have antiarrhythmic activity
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
CN114805112A (en) * 2022-05-31 2022-07-29 常州大学 PDE2 inhibitor amide derivative and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
EP0714660B1 (en) * 1989-06-23 2002-09-04 Syntex (U.S.A.) LLC Ranolazine and related piperazines for protecting skeletal muscles
AU632888B2 (en) * 1989-11-22 1993-01-14 Janssen Pharmaceutica N.V. Use of piperazine acetamide derivatives against reperfusion damage
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO2001062749A1 (en) 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1865945A4 (en) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd Combination therapy for endothelial dysfunction, angina and diabetes

Also Published As

Publication number Publication date
DE60126643T2 (en) 2007-10-31
ES2279790T3 (en) 2007-09-01
TWI286135B (en) 2007-09-01
NZ525259A (en) 2004-10-29
US20040029889A1 (en) 2004-02-12
KR20030044029A (en) 2003-06-02
HK1058364A1 (en) 2004-05-14
NO325220B1 (en) 2008-02-25
ZA200302990B (en) 2004-04-22
WO2002064576A1 (en) 2002-08-22
JP2004518725A (en) 2004-06-24
EP1339701A1 (en) 2003-09-03
NO20031797L (en) 2003-06-19
US6573264B1 (en) 2003-06-03
AU2002255466B2 (en) 2004-07-15
CA2426535A1 (en) 2002-08-22
ATE353882T1 (en) 2007-03-15
MXPA03003531A (en) 2005-01-25
CN1303074C (en) 2007-03-07
RU2243970C1 (en) 2005-01-10
IL155294A0 (en) 2003-11-23
US20030216409A1 (en) 2003-11-20
JP4138489B2 (en) 2008-08-27
DE60126643D1 (en) 2007-03-29
NO20031797D0 (en) 2003-04-22
SI1339701T1 (en) 2007-06-30
CN1628107A (en) 2005-06-15
EP1339701B1 (en) 2007-02-14
NO20031784L (en) 2003-04-23
IL155294A (en) 2009-02-11
HUP0303552A2 (en) 2004-04-28
US6849632B2 (en) 2005-02-01
NO20031784D0 (en) 2003-04-22
HUP0303552A3 (en) 2004-06-28
PL362004A1 (en) 2004-10-18
PT1339701E (en) 2007-03-30
AR034173A1 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
US6849632B2 (en) Heteroaryl alkyl piperazine derivatives
AU2002255466A1 (en) Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
US6552023B2 (en) Aralkyl substituted piperazine compounds
US6451798B2 (en) Substituted alkyl piperazine derivatives
US6677336B2 (en) Substituted piperazine compounds
JP3980885B2 (en) Substituted piperazine compounds
US6638970B2 (en) Substituted alkylene diamine compounds
AU2001238623A1 (en) Substituted piperazine compounds
HK1058364B (en) Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
US7125876B2 (en) Substituted heterocyclic compounds
JPS6293272A (en) Piperazine derivative and production thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION